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Abstract
The effects of 3-position substitution of 9-aminomethyl-9,10-dihydroanthracene (AMDA) on 5-
HT2A receptor affinity were determined and compared to a parallel series of DOB-like 1-(2,5-
dimethoxyphenyl)-2-aminopropanes substituted at the 4-position. The results were interpreted
within the context of 5-HT2A receptor models that suggest that members of the DOB-like series
can bind to the receptor in two distinct modes that correlate with the compounds’ functional
activity. Automated ligand docking and molecular dynamics suggest that all of the AMDA
derivatives, the parent of which is a 5-HT2A antagonist, bind in a fashion analogous to that for the
sterically demanding antagonist DOB-like compounds. The failure of the F3406.52L mutation to
adversely affect the affinity of AMDA and the 3-bromo derivative is consistent with the proposed
modes of orientation. Evaluation of ligand-receptor complex models suggest that a valine/
threonine exchange between the 5-HT2A and D2 receptors may be the origin of selectivity for
AMDA and two substituted derivatives.
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Serotonin has been implicated in a large number of processes including the regulation of
sleep, appetite, mood, aggression, perception, memory, and anxiety.1 At least 14 distinct 5-
HT G protein-coupled receptors (GPCRs) have evolved that are divided into seven main
families.2 Not surprisingly, alterations of 5-HT receptor activity have been shown to occur
in many psychiatric diseases including anxiety, depression, eating disorders, schizophrenia,
personality disorders, and many drug-induced psychotic states.2 Additionally, a number of
effective psychopharmacologic agents for diseases as diverse as depression, schizophrenia,
and anxiety have been developed that either specifically alter brain levels of serotonin or
bind to 5-HT receptor subtypes.1, 3 Over the last few years, all of the 5-HT receptor subtypes
have been cloned and sequenced.3, 4 Among the first to be studied were the 5-HT2A and 5-
HT2C receptors, and a significant body of reliable information has been accumulated
regarding these 5-HT2 receptors. Nevertheless, it is still not known with certainty how
serotonergic agents (or, for that matter, how the endogenous ligand 5-HT itself) interact at 5-
HT receptors. Crucial to an understanding of how serotonergic agents act, whether agonists,
partial agonists or antagonists, is some understanding of this drug-receptor interaction. A
novel class of high-affinity 5-HT2 agents5–9 has been described, the parent structure of
which (1a, 9-aminomethyl-9,10-dihydroanthracene, AMDA) is a 5-HT2 selective6
antagonist8 that appears to bind with the 5-HT2A receptor in a fashion distinct from classical
tricyclic agents.6, 9 As an anthracene derivative, AMDA is a fairly conformationally
restrained molecule. Its 9-aminomethyl group is preferentially oriented in a pseudoaxial10
conformation, and its tricyclic ring system exhibits a fold angle of about 147 degrees.5 Since
AMDA (1a) shares a phenylethylamine skeleton with phenylethylamine agonists such as
DOB (2b), potential binding mode relationships between AMDA and phenylethylamines
were evaluated by exploring the effects of substitution at the 3-position of AMDA and the
effects of the structurally analogous 4-position substitution of DOB-like phenylethylamine
derivatives upon the binding affinity. Possible modes of binding of AMDA analogs and
phenylethylamines were identified using 5-HT2A receptor models constructed from the
crystal structure of bovine rhodopsin. These studies have allowed us to formulate some
useful generalizations about binding modes of agonists versus antagonists as well as to
identify potential explanations for the observed receptor selectivity in the AMDA series.
RESULTS AND DISCUSSION
Chemistry
The structures of the target compounds 1a–h, 3a, 3b, 3d, 4a, 4b, and 4d are shown in Table
1. Compound 1a was prepared using a literature procedure.8 Compounds 2a–e and 2g have
also been previously reported in the literature, and their syntheses are discussed
elsewhere.11–13 Compounds 3a and 4a were obtained from commercial sources. Compound
4a was purchased as the free base and subsequently converted to the HCl salt14 using
ethereal HCl. Compound 3c was prepared as previously described.15
The synthesis of compounds 1b–h was not without difficulty. The initial plan was to convert
3-substituted anthrones to the desired aminomethanes in a straightforward fashion. This
route proved unsuccessful due to the rapid isomerization of anthrone to 9-anthrol under
acidic and basic conditions. Under most nucleophilic conditions, anthrone was converted to
the 9-alkyl anthracenes by dehydration of the intermediate 9-alkyl-9-hydroxy anthracene.
Treatment of anthrone with the Tebbe reagent16 did, however, provide 9-methylene-9,10-
dihydroanthracene in modest yields. It was expected that 9-methylene-9,10-
dihydroanthracene could then be oxidized to the 9-aminomethyl-9,10-dihydroanthracene
with BH3 and Chloramine T. Unfortunately, we were unable to generate large enough
quantities of the 9-methylene-9,10-dihydroanthracene for this route to prove practical. Our
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focus changed following a review of the synthetic strategy employed by the Nichols
group.17 The synthetic utility of an oxazoline as an ortho lithiating agent provided the key
intermediates essential to the synthesis of compounds 1d–h (Scheme 1). 4-Substituted
phenyloxazolines were used to provide compounds 1e and 1f. In these cases, it was reasoned
that strongly electron donating groups (methoxy and pentyloxy) in the para position would
facilitate the Friedel-Crafts cyclodehydration reaction (i, Scheme 1). Performing the
cyclodehydration reaction of the aminoalcohol intermediates 20 with weakly electron
donating substituents (R2 = hexyl, phenylpropyl) could lead to a mixture of two
regioisomers. Separation of the resulting 1- and 3-substituted isomers would prove difficult
since the free bases of compounds 1a–h are remarkably unstable. Exposure to air and/or
aqueous conditions causes a rapid (30 min–1 hour) degradation to unknown highly colored
compounds. Thus, 3-substituted benzaldehydes were used to generate compounds 1e, 1f, and
1g.
The general synthetic approach17 (Scheme 1) began with ortho lithiation of 16 using sec-
butyl lithium. The appropriate benzaldehydes were then added to the lithium anion at 0 °C.
The crude reaction mixtures were subjected to acidic hydrolysis giving rise to the lactones
17d,e,f,h in moderate overall yield. The lactones were hydrogenated in 2-PrOH with a
catalytic amount of HClO4 to give the acids 18d,e,f,h in good yields. The acids were then
reduced with BH3-THF and reoxidized with PCC to give the aldehydes 19d,e,f,h in
excellent yields. The aldehydes were converted to the appropriately substituted 2-amino-1-
hydroxy-(2-benzylphenyl)ethanols 20d,e,f,h using TMSCN with a catalytic amount of ZnI2
followed by LiAlH4 reduction in THF. The target compounds 1d–h were then prepared
through a cyclodehydration reaction using either PPA, Eaton’s Reagent, or methanesulfonic
acid. Compound 1g was prepared from the hydrobromide salt of compound 1e with BBr3 in
CHCl3.17
An alternate route was chosen for the synthesis of 1b due to the presence of a bromine
capable of undergoing lithium insertion (Scheme 1). The Grignard of 5 reacted in a 1,4
manner with 4-bromophenyl nitrostyrene (Scheme 2) to provide 6 by the method of
Ashwood et al.18 Deprotection of the alcohol 6 with HCl in methanol followed by the PPA
mediated cyclodehydration provided 8 in very low yield. The poor yield of the
cyclodehydration reaction can be attributed to the deactivating nature of the bromo
substituent. However, this route provided 8 in a regiochemically unambiguous manner.
SnCl2 reduction of the nitro group in 8 was chosen to eliminate any potential halogen loss.19
Compound 14, the precursor of 1c, was prepared as shown in Scheme 3. Compound 10 was
obtained by benzylic bromination (NBS in CCl4) of 4-bromo-2-methylbenzonitrile followed
by Friedel-Crafts alkylation with benzene. Conversion of the cyano group 10 to the aldehyde
was carried out in a stepwise manner using KOH in ethylene glycol20 followed by reduction
of the acid with BH3-THF and reoxidation to the aldehyde 13 with PCC in CH2Cl2. This
method was found to be superior to DIBAL reduction of the nitrile due to difficulties
encountered in the separation of the aldehyde from the starting materials even with the use
of aldehyde conjugation reagents such as sodium hydrogen sulphite. A modified Suzuki
coupling reaction was employed to introduce the phenylpropyl substituent using
allylbenzene/9-BBN followed by PdCl2(dppf) and NaOH in THF.21 The synthesis of 1c
from 14 was identical to that previously described for 1d,e,f,h (Scheme 1) by conversion of
the aldehyde to the 2-amino-1-hydroxy-[2-benzyl-4-(3-n-phenylpropyl)phenyl]ethanol
followed by cyclodehydration using Eaton’s Reagent.
4-Bromophenylethylamine (3b) was prepared by BH3-THF reduction of 4-bromophenyl
acetonitrile. 4-n-Hexylbenzoyl cyanide 26 was prepared as per the method of Olah et al22
using SnCl4 and TMSCN. The benzoyl cyanide was reduced to the target 4-n-
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hexylphenylethylamine (3d) using catalytic hydrogenation (10% Pd/C in acetic acid).23
Friedel-Crafts alkylation of 2-bromo-2-(4-bromophenyl)acetonitrile with benzene24
provided the diphenyl acetonitrile 27 which was reduced with BH3-THF complex to provide
the target 4b. Compound 4d was prepared by the reaction of 4-n-hexylbenzoyl chloride with
benzene and AlCl3 to provide 28 (4-n-hexylphenyl)(phenyl)methanone. Trimethylsilyl
cyanide was then employed in the preparation of the cyanohydrin 29 followed by reduction
of the hydroxy group with NaBH4 in TFA25 to provide 30 (2-(4-n-hexylphenyl)-2-
phenylacetonitrile). Reduction of the nitrile was then carried out using Raney Nickel under a
hydrogen atmosphere to provide 4d in moderate yield.
Biological Evaluation/5-HT2A Receptor Affinities
Radioligand binding data (5-HT2A receptor affinities) were obtained for each of the target
compounds (Table 1). The 5-HT2A receptor can accommodate a wide range of substituents
associated with the 3-position of AMDA (1a–1g; Table 1). Affinities varied only about 80-
fold (1b, Ki = 1.3 nM; 1g, Ki = 107 nM) within the series. With the exception of the 3-
hydroxy compound (1g, Ki = 107 nM), monosubstitution of AMDA (1a, Ki = 20 nM) either
does not change (1f, Ki = 23 nM) or increases affinity to a maximum of 15-fold (1b, Ki =
1.3) regardless of steric bulk or electronic character of the substituent. The effects of 4-
position substitution on the affinities of 1-(2,5-dimethoxy)-2-aminopropanes (DOX; 2a–2e)
are qualitatively similar in that each of these, with the exception of the hydroxy substituent
(2g, Ki > 50,000 nM), retains or enhances affinity. However, in the DOX series, the range of
affinity enhancement is much greater (2d, Ki = 2.5 nM; 2a, Ki = 5,200 nM) than for the
AMDA series with a maximum range of about 2,000-fold, excluding the 4-hydroxy
compound (2g) that shows no measurable affinity. Consistent with these observations, the
lipophilic character of the 4-position substituent of DOX has been shown to modulate
affinity over a broad range.13 These results suggest that the AMDA and DOX series may
interact differently with the 5-HT2A receptor. The principal structural feature distinguishing
AMDA from other phenylethylamines is the presence of a second, fused aromatic group.
Introduction of a second non-fused phenyl group to phenylethylamine, (i.e., 2,2-
diphenylethylamine) slightly increases affinity (3a, Ki = 16,800 nM; 4a, Ki = 4,610 nM).
Introduction of 4-substituents can enhance the affinity of phenylethylamine by about 280-
fold (3a, Ki = 16,800 nM; 3c, Ki = 60 nM; Table 1) and 2,2-diphenylethylamine by about
23-fold (4a, Ki = 4,610 nM; 4d, Ki = 200 nM). These increases in affinity (particularly with
respect to the phenylethylamines) are greater than the increases seen in the AMDA series
(1a, 1b; 15-fold), suggesting that there are differences in the modes of receptor interaction.
Thus, it appears that DOB-like compounds, AMDA derivatives and ring-opened AMDA
derivatives (i.e. 3 and 4) behave differently with respect to their binding at the 5-HT2A
receptor. This is perhaps not surprising given the fact that DOB is an agonist15 whereas
AMDA is an antagonist.8 At the very least, even if the two series bind in a comparable
fashion, they must interact preferentially with functionally and conformationally distinct
forms of the receptor. An alternative possibility is that the binding sites of agonists and
antagonists only share a common ammonium ion binding site with the remaining bulk of
each type of agent occupying completely different domains within the receptor.
Receptor Complex Models
There are numerous examples of similar compounds binding quite differently to a common
receptor as well as ligands with multiple binding modes at a single receptor.9, 26 Analysis of
early 5-HT2A receptor models led us to consider two general areas of steric accessibility, as
depicted in Figure 1: Site 1 (TM3 flanked by TM4, TM5, and TM6) and Site 2 (TM3
flanked by TM1, TM2, TM6, and TM7). The presence of two distinct binding sites for
GPCRs has been noted in the literature.27 Previously, consideration of ligand SAR and
receptor mutagenesis data prompted us to provisionally consider Site 1 the “agonist site” and
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Site 2 the “antagonist site.”28–30 Similar suggestions have also been made for the 5-HT1A
receptor.31 Subsequently, the method used here to select “agonist-biased” and “antagonist-
biased” receptor models from a population of conformationally distinct receptor models
(described in detail in the Experimental Section) has identified Site 1 as an agonist binding
site and Site 2 as an antagonist binding site. The selected models identified in this way are
thus referred to in this work as the agonist and antagonist receptor models, respectively. The
computational methodology used in this work was designed to mimic the current model of
protein-ligand binding in which the ligand selects a particular receptor conformation from an
ensemble of metastable states.32 Site 1 and Site 2 overlap, and the shared region between
these sites includes residues that are a part of helices TM3 (D1553.32 and S1593.36) and TM6
(W3366.48 and F3396.51).33
Whenever receptor homology models are generated whose purpose is to model the
interaction of an agonist with the receptor, the accuracy of these models is called into
question (more so than for antagonist-interaction models) since until very recently only
inactive or ground-state rhodopsin crystal structures were available as homology modeling
templates. More precisely, the additional requirement of an agonist to activate or trigger the
receptor is thought to involve large-scale movements of at least part of the secondary
structure of the receptor, making the activated receptor’s conformation significantly
different from the inactive state’s conformation. Currently, such large-scale changes in
conformation are not routinely incorporated into homology models. Recent crystallographic
evidence, however, suggests that the conformation of the activated form of bovine rhodopsin
does not significantly change in the ligand binding region: Salom et al.34 have obtained a
crystal structure, at 4.15 Å resolution, of the deprotonated form of Metarhodopsin II (Meta
II), the fully activated state of rhodopsin. This structure is strikingly similar to the structure
of ground-state rhodopsin in the transmembrane and extracellular loop regions, where ligand
binding sites are located. The authors thus conclude that “rhodopsin is a good template for
homology models of other GPCRs used in docking calculations of both agonists and
antagonists, because ground-state and photoactivated rhodopsin are structurally similar”.34
Other studies have proposed that a cluster of residues on TM6 in Site 1 form a molecular
“toggle switch” that is responsible for the activation of rhodopsin-like GPCRs.35 This work
utilizes the ground-state conformation of bovine rhodopsin (A chain of 1U19; 2.2 Å
resolution) as a homology modeling template. However, the conformations of the sidechains
(and the backbone to a lesser degree) are allowed to vary from that of the template
rhodopsin structure.
Viewed from the perspective of the ligand, in the most general terms it is usually observed
that structures of antagonists differ from the endogenous neurotransmitters and other
agonists in that they either lack key functional groups or present molecular features in areas
of space not occupied/utilized by any portion of the agonist (i.e., an “accessory site”), or
both.36 For example, while 5-methoxytryptamine is a serotonin agonist, tryptamine is a
partial agonist (see the review by Glennon, Westkaemper and Bartyzel37); also, it has been
shown that 2-phenyltryptamines are high-affinity 5-HT2A receptor antagonists.38 Similarly,
LSD is an agonist or partial agonist whereas 2-bromo LSD is an antagonist.39 In the DOX
series, compounds with small substituents at the 4-position are agonists and those with bulky
substituents such as phenylpropyl are antagonists.13, 15 In the latter case, the 2,5-dimethoxy
groups of 1-(2,5-dimethoxy-4-(3-phenylpropyl)phenyl)-2-aminopropane (2c), functional
groups characteristically required for agonist activity, are no longer required for binding
and, in fact, the desmethoxy parent 3c has comparable affinity to the 2,5-dimethoxy
substituted derivative.13, 15 A similar observation can be made for 2d and 3d. It has been
hypothesized that phenylalkylamines with small 4-position substituents (e.g. 2a, 2b, 2e) bind
differently from those with bulky 4-position substituents (e.g. 2c, 2d). Models of complexes
of the 5-HT2A receptor and DOB support the notion that there may be limited bulk tolerance
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at the 4-position for some modes of binding. Bound within Site 1, substituents at the 4-
position of DOX project into the interfacial region between TM5 and TM6 (see Figure 2a
for an example). Preliminary modeling studies have indicated that whereas 4-methyl and 4-
ethyl substituents appear to be tolerated in the DOB-like series, successively adding
methylene units to the 4-position of 1-(2,5-dimethoxy-4-ethylphenyl)-2-aminopropane
bound to the receptor actually causes a displacement of the of the aromatic ring (2.3 Å) from
the initial site on minimization. The bound ligand 2d is rapidly displaced from its initial site
during dynamics simulations (100 ps, 300° K, range constraint NH-OD155, 1.3–2.6Å, helix
backbone constrained) whereas DOB (2b) is not. Another possible binding mode would
place large 4-position substituents in Site 2 (Figure 1). A 5-HT2A receptor model with the
phenylethylamine 3d bound in Site 2 did not show displacement of the aromatic ring and the
ligand remained in the binding site on dynamics simulation.
The effects of N-alkylation and N-benzylation appear to support the notion that DOB and
AMDA interact with the receptors differently. In the case of both 5-methoxytryptamine and
DOB, successive N-methylation decreased affinity but N-benzyl DOB and N-benzyl-5-
methoxytryptamine have slightly higher affinities (2- to 6-fold) than their parents.40 In the
AMDA series, successive N-methylation also decreased affinity but, unlike the DOB and 5-
methoxytryptamine series, N-benzylation decreased affinity (36-fold).6
Information from mutagenesis experiments further suggests that AMDA and
phenylalkylamines (i.e. 3) or DOX analogs (i.e. 2) with small 4-position substituents (e.g.
DOB, DOI) bind differently, at least with respect to F3406.52. In the current models, the
sidechain of F3406.52 is at the interface between TM5 and TM6, pi-stacked with the
sidechain of F2435.47 (Figure 2a). Any effect that an F340 mutation might have on ligand
affinity could either be due to changes in a direct, ligand-receptor van der Waals interaction,
or an indirect effect caused by a change in the shape of the helical bundle. The mutation
F340L has been shown to decrease affinity of agonists, but generally hasno effect on the
binding of classical antagonists.41 AMDA (1a) and the bromo analog 1b both bind to the
mutant receptor equally well (3-fold decrease and no change in affinity, respectively)
compared to their binding at the wild type receptor (Table 2). The same mutation has little
effect on ketanserin affinity but essentially abolishes DOI binding (an approximately
14,000-fold decrease).41 This is entirely consistent with AMDA and AMDA derivatives
binding in a completely different fashion from DOI, at least with respect to the F3406.52
position in the receptor structure. The affinities of the two 2,2-diphenylaminoethane
compounds (Table 2) are either unchanged or increased by F340L mutation (4a, Ki = 4,140
nM; 4b, Ki = 3.5 nM) relative to the wild type (4a, Ki = 4,610 nM; 4b, Ki = 260 nM). Again,
these results support the notion that, with respect to F340, the diphenyl compounds (4a, 4b)
behave differently from phenylethylamines and most likely bind in a mode distinct from that
of the analogous tricyclic compounds 1a and 1b. Changes in the sidechain conformation of
F340 have been previously invoked to explain affinity enhancement for some classes of
compounds with the F340L mutant.30
Model Construction
In the following subsections, computationally-derived 5-HT2A GPCR models are described
that separately model the binding characteristics of selected agonists and antagonists.
‘Agonist-biased’ and ‘antagonist-biased’ receptor models were generated in the following
way: Using the MODELLER software package, a population of 100 5-HT2A
conformationally distinct receptor models derived from bovine rhodopsin was generated.
The automated docking program GOLD was then used to separately dock both
stereoisomers of a high-affinity agonist (DOB, 2b) and an antagonist (ketanserin) into each
of the 100 5-HT2A receptor models (Chart 1). Based on the quality of the docked receptor-
ligand complexes and information from site-directed mutagenesis, one of the 100 models
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was selected to be the ‘agonist’ 5-HT2A receptor model and another was selected as the
‘antagonist’ 5-HT2A model (Supplemental Figure 1). Both stereoisomers of each of the
compounds listed in Table 1 were then docked into both the agonist and antagonist receptor
models. Docking scores and information from mutagenesis data were then used to select the
most appropriate receptor (agonist or antagonist) for each ligand.
Agonist Receptor Complex Models
Both isomers of DOB were found to favorably interact with the selected agonist receptor
model, and in a nearly identical fashion (Supplemental Figure 2). The most significant
difference in the binding modes of the stereoisomers is in the position of the protonated
amine; however, both isomers are able to form a salt bridge with D1553.32. The proposed
binding pocket for R(−)-DOB (R(−)-2b) is shown in Figure 2a, and residues that can
potentially interact with it are reported (Supplemental Table 1). The aromatic ring is
associated most closely with W3366.48, F3396.51 and F3406.52. The 4-bromo substituent is
oriented toward the interfacial region between TM5 and TM6 and the 2-methoxy group of
DOB accepts a hydrogen bond from N3436.55. The 5-methoxy group is near S1593.36,
T1603.37 and S2425.46, and can potentially form hydrogen bonds with these residues to
further stabilize the receptor-ligand complex. Additionally, a lipophilic interaction occurs
between the methyl of the 5-methoxy group and W3366.48. Other nearby aromatic residues
that can potentially interact with the aromatic ring of DOB include F2435.47 and F3406.52.
F3396.51 is in a position to further stabilize the ammonium-D1553.32-S1593.36 complex via a
π-cation interaction.
Recently, it was reported42 that R(−)-DOB and S(+)-DOB both have high affinity for the 5-
HT2A receptor, but with the R(−)-isomer showing a somewhat lower Ki than the S(+)-
isomer (R(−)-DOB, Ki = 0.29 nM; S(+)-DOB, Ki = 1.9 nM). Employing modeling
techniques, the authors showed that the R and S isomers of DOX phenylethylamines can
bind in a very similar fashion, but that the orientation of S2395.43, F2405.44, F2435.47,
F2445.48 and F3406.52 differed depending on which isomer was docked into the receptor.
Although our modeling technique places DOB in the same location as the previous authors,
the model described here features a pi-stacked interaction between F3406.52 and F2435.47.
Disruption of this association (either through a point mutation or via interactions with a
ligand) may alter the location and orientation of the helices within the helix bundle. As
mentioned by Parrish, et al.,42 the cognate residues in bovine rhodopsin, F2125.47 and
A2696.52, have been shown to have highly coupled evolution as part of a physically
connected network that links distant functional sites in the tertiary structure of G-protein
coupled receptors (GPCRs).43 The close association of the DOX ligands with F3406.52
would also explain why the F340L mutation nearly abolished44 the affinity of DOI for the 5-
HT2A receptor. Both enantiomers of DOB and DOI have a high affinity for the 5-HT2A
receptor42 and were docked into the agonist receptor model in a nearly identical manner, the
only difference being the position of the β-methyl group (Supplemental Figure 2). In our
agonist receptor model, DOB occupies the same binding pocket that has been predicted for
the endogenous ligand 5-HT.45–47
The proposed binding mode for DOB features the ligand accepting a hydrogen bond from
N3436.55. An analysis of the primary sequences of the known human 5-HT receptor
subtypes reveals that only 5-HT2A, 5-HT2B, 5-HT2C, 5-HT4 and 5-HT6 receptors feature
asparagine at 6.55, although other subtypes have sidechains capable of donating a hydrogen
bond at this position (6.55 = Ser in 5-HT1B, 5-HT1D and 5-HT7). The Psychoactive Drug
Screening Program (PDSP) Ki Database (http://pdsp.med.unc.edu/pdsp.php) contains entries
for DOB as the test ligand for 5-HT1 and 5-HT2 receptor subtypes. In all cases, the affinity
of DOB for the 5-HT2 subtypes was much greater (0.6 to 152 nM) than for the 5-HT1
subtypes (556 to 6327 nM). This is consistent with the hypothesis that N6.55 contributes
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significantly to the observed high affinity of DOB at the 5-HT2 subtypes. The 6.55 position
has also been shown to be important for the binding of other agonists and antagonists at
serotonergic and other closely related aminergic GPCR subtypes.48–53
The ligand-accessible and highly conserved residues W3366.48 and F3406.52 of the
“aromatic cluster”54 in Site 1 have been proposed to be part of a rotameric “toggle
switch”35, 55 in which the χ1 torsion angles of these residues determine, in conjunction with
the proline kink in TM6, the proximity of the intracellular ends of TM3 and TM6 (i.e. the
“ionic lock”56). The χ1 conformations that correspond to the “activated” receptor are trans
for both 6.48 and 6.52, which is consistent with the putative agonist model presented here.
Taken together, this information along with the examples given above provide additional
evidence that the agonist model described here is accurate.
AMDA (1a) was successfully docked into Site 1 in the agonist model with the basic amine
H-bonded to both D1553.32 and S1593.36. One of the aromatic rings is oriented toward the
cluster of hydrophobic residues on TM6, interacting with I1633.40, F2435.47, W3366.48 and
F3406.52; the second aromatic ring of AMDA interacts with V1563.33, I2064.56 and
L229xl2.52. Importantly, it is shown here (Table 2) that mutation of F3406.52 to leucine has
little effect on the binding of antagonists like AMDA (1a). In contrast, the F3406.52L
mutation had dramatic effects on the binding of DOI, an agonist very similar to DOB (2b).
This would indicate that 1a and 2b bind differently with respect to F3406.52.
AMDA analogs with small substituents at the 3-position (1b, 1e, 1g) are oriented in Site 1 in
a manner analogous to that of AMDA. However, for 1e and 1g there are no nearby H-bond
donors or acceptors to effectively interact with the polar functionality at the 3-position
(W3366.48 is close, but with poor H-bond geometry). For the larger, more flexible
hydrophobic analogs (1c, 1d, 1f), the 3-position substituent is either directed toward the
opening of the receptor cavity (for S-isomers) or folds back onto the dihydroanthracene core
(for R-isomers), a characteristic that is statistically unlikely based upon an analysis of crystal
structures of ligand-receptor complexes.57, 58 In the phenylisopropylamine series, DOB
analogs with small substituents at the 4-position (2a, 2e, 2g) dock into the receptor in a
similar fashion as DOB, with the aromatic ring associated with W3366.48, F3396.51 and
F3406.52 and the methoxy groups interacting with S1593.36, T1603.40, S2425.46 and
N3436.55. The position of the aromatic ring for these compounds is close to the position of
the aromatic ring in AMDA most closely associated with the aromatic cluster on TM6. As
with the AMDA analogs substituted with small polar substituents at the 3-position, there is
no H-bonding partner for the small polar substituents at the 4-position of the DOB analogs.
This is consistent with the low observed binding affinities for these compounds. For DOB
analogs 2c and 2d, the large 4-position substituents are folded back onto the ligand’s
aromatic ring (both isomers), analogous to the AMDA analogs (R-isomer) with large 3-
position substituents. In order to accommodate the bulk of the large substituent, the aromatic
ring is displaced toward TM4, and the H-bonds with the methoxy groups are diminished or
eliminated. The phenylethylamine analogs 3a–d dock with conformations that are similar to
their corresponding DOB analogs, and the diphenylmethylamine analogs 4a, 4b and 4d dock
in the receptor like their corresponding AMDA analogs 1a, 1b and 1d.
Antagonist Receptor Complex Models
The energy-minimized ketanserin-receptor model is depicted in Figure 2b (nearby residues
are listed in Supplemental Table 1). In addition to the hydrogen bond formed between the
ammonium ion in the ketanserin piperidine ring and the conserved D1553.32, three other
hydrogen bonds are evident: S1312.61 bonds with the p-fluorobenzoyl carbonyl oxygen,
S1593.36 bonds with the N1 quinazolinedione nitrogen atom, and S3737.46 bonds with the
carbonyl oxygen at position 2 of the quinazolinedione ring system (Figure 2b). Hydrophobic
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residues surrounding the remainder of the ligand include W1513.28, I1523.29, V1563.33,
L229xl2.52, W3366.48, V3667.39, W3677.40 and Y3707.43.
To provide an indication of the correctness of the docked solution, relevant mutagenesis
binding data were collected from the literature; these are listed in Table 3. As [3H]ketanserin
is often used as the radioligand in competitive binding assays involving the 5-HT2A receptor
and its mutants, Kd values were frequently available. Many of the mutations listed in Table 3
involve residues that are not located in the binding crevice of the receptor. Others involve
residues that are conserved across all GPCRs and are probably required to maintain the
structural integrity and/or basic functioning of the receptor. Several of the mutations involve
the conserved aspartate D1553.32, and the result of mutating this residue to something other
than aspartate at this site is a near or complete loss of affinity for ketanserin. Presumably this
mutation would also disrupt the binding of many other small basic amine-containing
compounds, agonists and antagonists alike. Other mutations are more relevant to the binding
of ketanserin itself. Mutation of serines S2395.43 and S2425.46 on TM5 to alanine has no
significant effect upon the binding of ketanserin. This is consistent with the proposed model
as ketanserin does not approach TM5. The F2435.47 and F3406.52 mutations each minimally
decrease the binding of ketanserin. While neither F2435.47 nor F3406.52 are within van der
Waals interaction distance with ketanserin, the small decreases in affinity at these mutated
positions could be accounted for by indirect destabilization of the binding site. The
S1593.36A and S1593.36C mutations were found to have almost no effect on the affinity of
ketanserin. While this may seem to contradict our proposed model because S1593.36
participates in a hydrogen bond, the actual situation is probably more subtle. For example, it
has been shown59 that the entire quinazolinedione ring system may be replaced with a with a
phenylethyl fragment lacking H-bonding capability without significant loss of affinity (less
that 2-fold decrease in Ki). If ketanserin binds as proposed, then this would suggest that the
hydrogen-bonding capability of S1593.36 is not required, and thus consistent with the
mutagenesis data. W3366.48A was found to have one of the largest effects on ketanserin
binding (a 900-fold decrease). This is consistent with the model because there is a
substantial amount of hydrophobic surface contact area between the quinazolinedione ring
system and the indole ring of W3366.48. Similarly, mutation of F3396.51 to alanine or leucine
results in moderate decrease (8- to 25-fold) in ketanserin’s binding affinity due to the loss of
hydrophobic bulk in the region. The F3396.51Y mutation introduces a phenolic group into an
area occupied by the fused phenyl ring of the quinazolinedione moiety, resulting in a
moderate decrease in binding affinity. Mutation of F3406.52 to alanine or leucine has no
significant effect. This is also consistent with the model because this residue is at a distant
location in Site 1 and is not expected to interact with ketanserin. The effect of the F3406.52Y
mutation is substantial with a 70-fold decrease in binding affinity. Mutation to tyrosine at
this position would introduce a hydroxyl group into the lipid bilayer. This could possibly
facilitate the disruption of the F2435.47-F3406.52 interaction and the binding cavity as a
result, since the tyrosine OH group would presumably prefer to be located in the more polar
interior of the receptor. The W3677.40L mutation abolished ketanserin binding and nearly
abolished the binding of small agonists like 5-HT and DOM that would be expected to bind
completely within Site 1.44 As well as providing a site of interaction for ketanserin, this
would seem to indicate that W3677.40 forms part of an extended Site 1, as mentioned earlier.
Alternatively, W3677.40 may also interact with W761.34. Such an interaction may serve to
stabilize the helical bundle, at least for the serotonin receptor subtypes, in which tryptophan
is uniformly conserved at the 7.40 position, and a hydrophobic residue (tryptophan for the 5-
HT2 subtypes) appears at the 1.34 position in all but the 5-HT1D receptor (serine for 5-
HT1D). Finally, the Y3707.43A mutation decreases ketanserin’s affinity by nearly 20-fold.
This seems reasonable, considering the relatively close proximity of Y3707.43 to the
piperidine ring of the ligand. In summary, these results are consistent with our proposed
binding mode for the antagonist ketanserin.
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Our approach in selecting a receptor for antagonists involved choosing the most highly
ranked (as measured by the ChemScore fitness function) receptor-ligand complex that
exhibited reasonable conformations for both ligand and receptor; in this particular case the
ketanserin test ligand adopted a twist-boat conformation. Twist-boat forms of cyclohexane
are known to have energies that are about 5.5 kcal/mol higher than the corresponding
“chair” forms;60 those for piperidine would be expected to exhibit a similar increase in
energy. At first glance, then, this particular docked solution for ketanserin may seem
unreasonable. However, it has been noted that in many cases, the conformation of the
docked ligand is one that may not even be close to a local energy minimum.57, 58, 61, 62
Very recently, Dezi, et al.63 have generated a 5-HT2A model suited to the binding of
butyrophenone antipsychotics using methodology that is quite similar to that described here.
In their study, they present a ketanserin binding mode that is essentially “backwards” when
compared to the ketanserin model proposed here (i.e. the p-fluorobenzoyl group is oriented
toward TM5 instead of toward TM2). However, the authors go on to mention that there are
likely to be multiple binding modes that contribute to the observed affinity for slender,
roughly symmetric ligands (wherein a centrally positioned cation is flanked by two sets of
roughly equivalent hydrogen bonding groups) such as ketanserin and the butyrophenones.
Indeed, in our own experience, the GOLD-derived solutions for ketanserin usually dock in
either of these two major orientations. Thus, it is possible that there exist alternate valid
docked solutions for ketanserin.
Qualitatively, ketanserin and 3-phenylpropyl-AMDA (1c) are docked in much the same way
(Figure 2e), with the p-fluorobenzoyl group occupying nearly the same region of space as
the phenyl group of the phenylpropyl substituent of 1c, and the quinazolinedione ring
system is in roughly the same area as the tricyclic ring system of 1c (the rings of 1c are
oriented toward TM6; the ketanserin quinazolinedione rings are oriented toward TM5).
Significantly, all four isomers of 1c (most likely acting as antagonists) received very high
scores when docked into the ketanserin-selected antagonist model (Supplemental Figure 3),
indicating that both ketanserin and 1c can recognize and engage the same receptor
conformation.
The docked and minimized AMDA-5-HT2A model is depicted in Figure 2c (nearby residues
are listed in Supplemental Table 1). When compared to 5-HT and traditional
phenylethylamine-derived agonists, AMDA lacks both agonist-like functional groups (e.g.
the 5-OH group of 5-HT or the 2,5-dimethoxy substituents of DOB) and presents an added
feature, the “second” aromatic ring. The shape of the binding pocket in the antagonist
receptor model exquisitely compliments the general shape of the AMDA molecule, and that
of its tricyclic core in particular (Figure 1b). The AMDA molecule is situated in the receptor
in a distinctly different location than DOB, although AMDA and DOB do interact with
common residues on TM3 (D1553.32) and TM6 (Y3396.51). Effectively situated between
TM3 and TM7, AMDA binds in the receptor such that one aromatic ring orients toward
TM6 and the other is oriented toward TM1. The ammonium group of AMDA interacts with
D1553.32 and also can interact (as suggested by molecular dynamics experiments) with the
backbone carbonyl oxygen atom of C227xl2.50, one of the cysteines of the disulfide bridge
anchoring the e2 loop to the extracellular end of TM3. The aromatic ring that is oriented
toward TM1 is sandwiched between W1513.28 and Y3707.43; the ring oriented toward TM6
forms π-π interactions with D1553.32. The docked AMDA solution also forms close
hydrophobic contacts with V3667.39, which could have implications for the selectivity of
AMDA for 5-HT2A over the dopaminergic D2 receptor (vide infra).
Site 2 is lined most notably with several polar residues (T811.39, S1312.61, S1593.36,
S3737.46) and hydrophobic residues (M1282.58, W1513.28, V3667.39, Y3707.43). The
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distribution of polar and hydrophobic residues is such that an amphiphilic cavity is created
between the relatively polar faces of TM1 and TM2 and the lipophilic face of TM7. It is
possible that the amphiphilic nature of the site is the characteristic that allows both relatively
polar (e.g. 1e, 1g), non-polar (e.g. 1c, 1d), and mixed (e.g. 1f) groups to bind with
reasonably high affinity almost without discrimination, as described in the following
paragraphs.
The 3-position substituents of AMDA are directed either toward TM1 and TM2 (for S-
isomers) or toward TM3 and TM6 (for R-isomers). The tricyclic core of the AMDA analogs
with small substituents (1b, 1e, 1g) adopts a position in Site 2 that is the same as for the
parent AMDA. For the small polar groups (1e, 1g), H-bonding takes place with either
T811.39 and S1312.61 (S-isomers) or with S1593.36 and S3737.46 (R-isomers). The top-ranked
GOLD-docked solution for (S)-1g features a hydrogen bond to both T811.39 and S1312.61
(Figure 2d). The more elongated shape of Site 2 relative to Site 1 allows for larger 3-position
substituents (1c, 1d, 1f, 1h) to dock in a more fully extended conformation. For S-isomers,
the substituent is directed toward and interacts with Y3707.43. In order to accommodate the
large substituent, the tricyclic core is shifted away from the e2 loop and toward Site 1. This
is possible due to the basic amine’s ready accessibility to both sidechain oxygen atoms on
D1553.32. The docked and minimized (S)-3-phenlypropyl-AMDA (S-1c) interaction model
is depicted in Figure 2e (nearby residues are listed in Supplemental Table 1). The tricyclic
core of compound 1c interacts with residues on TM3 (D1553.32 and S1593.36) and on TM6
(M3356.47, W3366.48 and F3396.51). The bulky 3-position substituent is located in the cavity
bounded by TM1, TM2 and TM7 (Site 2), with the aromatic portion anchored at Y3707.43.
For R-isomers with large 3-position substituents, the R-group is either directed toward
S1593.36, W3366.48 and M3656.47 (1d, 1f) or the AMDA core is inverted in an “upside-
down” fashion, with the R-group interacting with Y3707.43 as described for the S-isomers
(1c).
The bis-substituted compound 1h (Table 1) was initially evaluated in an attempt to bridge
and interact simultaneously with both Sites 1 and 2. The 6-methoxy group was expected to
interact with a hydrogen bond donating residue of Site 1, with the n-hexyl group anchored in
Site 2. While monosubstitution with either an n-hexyl (Ki = 7.0 nM, 1d) or a methoxy group
(Ki = 7.5 nM, 1e) enhances affinity relative to AMDA (Ki = 20 nM, 1a) to a small extent,
the bis-substituted compound (Ki = 43 nM, 1h) has a lower affinity than either the
unsubstituted compound (1a) or the monosubstituted derivatives (1c, 1d). At very least, the
bifunctional nature of 1h does not greatly enhance affinity. The docked solution of (R)-1h
(not shown) in the antagonist model reveals that the ligand primarily occupies Site 2 and that
the n-hexyl group is situated in a similar fashion to the phenylpropyl group of (S)-1c. The
methoxy group of (R)-1h is directed toward TM6 and interacts with M3356.47, but there are
no H-bond donors nearby with which the methoxy oxygen can interact. For (S)-1h, the
positions of the substituents are reversed: the methoxy group H-bonds with T811.39 and/or
S1312.61 and the n-hexyl group is associated with W3366.48 and M3356.47.
DOB-like isopropylamines with small substitutions at the 4-position of the phenyl ring (2a,
2b, 2e, 2g) are docked into the antagonist model such that the aromatic ring is situated
between W1513.28 and Y3707.43. Those that are nonpolar (2a, 2b) orient either the 2-
methoxy group toward S226xl2.49 or the 5-methoxy group toward S771.35 (both isomers).
Those that are polar (2e, 2g) orient the 4-substituent to interact with either T811.39 or
S1312.61 (both isomers). DOB-like isopropylamines with large substituents at the 4-position
place the phenyl ring between D1553.32 and V3667.39 (both isomers) as depicted in Figure 2f
for compound (R)-2c. Such compounds are stabilized in the binding site via hydrogen bonds
with D1553.32 and S1593.36 (ligand ammonium group) as well as W1513.28 and S226xl2.49
(5-methoxy group), though the latter H-bonds are far from ideal. An intramolecular
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hydrogen bond is also possible between the 2-methoxy group oxygen atom and the
ammonium group. The large 4-position substituent is directed toward the same pocket in
Site 2 as large 3-position substituents of the AMDA analogs, and is stabilized in an
analogous manner. Supplemental Figure 4 shows the similarity in binding modes of 1c and
2c in the antagonist receptor binding site. The lack of H-bonding with the methoxy groups is
consistent with the observation that they are not needed when the 4-position is
phenylpropyl.15 The phenylethylamine derivatives 3a–d dock into Site 2 in the same way as
do the isopropylamine analogs 2a–d, and the diphenylmethylamine derivatives (4a, 4b, 4d)
dock similarly to their respective AMDA derivatives.
There is very little mutagenesis data available to lend insight into the nature of the
interaction between the AMDA class of compounds and the 5-HT2A receptor specifically.
However, residues that contribute to the amphiphilic nature of Site 2 and have been
implicated to be important for the binding of ligands into the antagonist model have also
been implicated to be important for ligands binding in other closely-related aminergic
GPCRs. These include the residues at positions S1312.61,64, 65 W1513.28,65–68
Y3707.43,44, 69–71 and V3667.39.68, 72–78 Once again, when taken together, these examples
provide evidence that Site 2 is accessible in the 5-HT2A receptor and that the antagonist
model described here is accurate.
The results of the docking experiments may be summarized as follows: Each of the tested
compounds containing a phenylmethyl, n-hexyl or n-pentyloxy group exhibited significant
binding affinity (Ki <= 200 nM), and it was these compounds that tended to show the
greatest preference for Site 2 (antagonist model) over Site 1 (agonist model) based on the
ChemScore fitness function used by the GOLD docking program (Supplemental Table 2).
Compound 2c has been shown to have antagonist character,15 which is consistent with its
preference for the antagonist model. The relatively high affinity of AMDA derivatives with
small polar substituents (1e, 1g) is likely due to the stabilization of both isomers in the
amphiphilic Site 2. The high-affinity compounds with small nonpolar R-groups (1a, 1b, 2b)
tended to favor the agonist model to a greater degree. This makes sense for the agonist 2b,
where there is more extensive and effective hydrogen bonding with the methoxy groups,
which have been shown to be necessary for high affinity in these compounds.13, 15 In
addition, the F3406.52L mutation has been shown to abolish the affinity of DOI, a compound
closely related to 2b (DOB). The preference of the antagonist 1a for Site 1 may be an
anomaly, however, since the AMDA core is in close proximity to F3406.52, yet the
F3406.52L mutation has little effect on its binding affinity. Similarly, 4b may actually bind
in Site 1 rather that in Site 2 as predicted from the fitness function. Further mutagenesis
testing and functional assays will be necessary, however, in order to unequivocally resolve
the binding modes of these compounds.
Receptor Selectivity
As shown in Table 4, AMDA and two of its high affinity analogs are quite selective for 5-
HT2 receptors. 5-HT2A affinity is between 900- and 7000-fold higher than D2 receptor
affinity. There is little selectivity for 5-HT2A versus 5-HT2C receptors (2- to 9-fold).
Selectivity for the 5-HT2A receptor over the serotonin and norepinephrine transporters is
pronounced for 1a and 1b (between 500- to 3,000-fold) and less pronounced for 1d (60- and
120-fold). Since selectivity against the D2 receptor is not strongly influenced by the nature
of the 3-position substituent, the observed selectivity is probably attributable to the AMDA
nucleus itself. Examination of the docked AMDA structure (Figure 2c) along with an
alignment of the 5-HT2A and D2 receptor sequences (Figure 3) allows the identification of
residues that are likely responsible for the selectivity of AMDA for the 5-HT2A/C receptors.
Residues in the antagonist model that possess a heavy atom within a 4.5-Å radius of any
heavy atom in AMDA are highlighted in yellow boxes in Figure 3. Within this set of
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residues, one variant position in TM1 (S771.35), one position in TM2 (S1312.61), three in
TM3 (W1513.28, I1523.29 and S1593.36), one in the e2 loop (S226xl2.49) and one in TM7
(V3667.39) that face the central cavity of the 5-HT2A receptor model can be identified. It is
possible that each of these residues contribute to the selectivity of ligands for 5-HT2A over
D2. The cognate residue of S771.35 in the 5-HT2A receptor is Y371.35 in the D2 receptor. The
additional steric bulk of the tyrosine sidechain (compared to serine) would be sufficient to
displace AMDA from its preferred binding site. The cognate residue of W1513.28 in the D2
receptor is F1103.28. Although tryptophan and phenylalanine are both aromatic, the close
association of the sidechain at this position with the aromatic ring system of AMDA (3.6 Å)
would suggest that even small differences in sidechain topology could take on greater
significance for binding. S226xl2.49, whose equivalent residue in D2 is E181xl2.49, is adjacent
to the disulfide bond anchoring the e2 loop to the top of TM3. In this position, the sidechain
of a glutamic acid residue could extend into AMDA’s proposed binding site, placing its
polar carboxyl group in approximately the same location as one of the aromatic rings of
AMDA. Perhaps the most influential residue in determining 5-HT2A/C/D2 selectivity is
V3667.39, which is equivalent to position to T4127.39 of the D2 receptor, and whose
sidechain heavy atoms are within 4 Å of three heavy atoms (3.54, 3.85 and 3.93 Å) of the
Site 2 aromatic ring system of AMDA in the antagonist model. As mentioned earlier, in
adrenergic receptors, the presence of an alanine or threonine instead of the asparagine
residue at this position has been shown to be responsible for subtype selectivity within the
serotonin receptor family, particularly with respect to the ability to bind β-adrenergic
antagonists such as propranolol.72, 73 It is possible that placement of a polar threonine near
the AMDA aromatic ring may be unfavorable enough to account for the lower affinity of
AMDA and AMDA derivatives with the D2 receptor. This hypothesis could be tested by
evaluation of the V366T mutant of the 5-HT2A receptor.
CONCLUSION
Previous investigations have provided evidence that phenylalkylamines can be agonists or
antagonists depending on the nature of the 4-position substituent.13, 15 It has been speculated
that the difference in functional behavior is a reflection of the possibility that agonist and
antagonist phenylalkylamines bind in a different fashion with the 5-HT2A receptor. A
comparison of the effects of a parallel series of aromatic substituents based on the tricyclic
5-HT2A antagonist AMDA suggests that the AMDA-series may bind in a fashion similar to
that of antagonist phenylalkylamines with bulky aromatic substituents. Differential effects of
the F340L mutation observed for the AMDA series and phenylethylamine agonists supports
this hypothesis. Automated docking studies with ligands docked into 5-HT2A models are
consistent with the hypothesis that agonists bind in a fashion such that the aromatic rings are
oriented toward the fifth and sixth transmembrane helices (Site 1), a region of limited bulk
tolerance, whereas antagonists place the substituted aromatic ring near the seventh and
toward the first, second and seventh transmembrane helices (Site 2) in a region of greater
bulk tolerance. AMDA and two substituted derivatives were found have a high degree of
selectivity against the D2 receptor and the serotonin (SERT) and norepinephrine (NET)
transporters, but were non-selective with respect to the 5-HT2C receptor. Analysis of the
putative binding modes of AMDA and related derivatives indicate that a valine/threonine
exchange between 5-HT2A/C and D2 receptors contributes significantly to the observed
selectivity of these compounds.
EXPERIMENTAL METHODS
Synthesis
Melting points were determined using a Thomas-Hoover melting point apparatus and are
uncorrected. Proton magnetic resonance (1H NMR and 13C NMR) spectra were obtained
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with a Varian Gemini 300 spectrometer, using tetramethylsilane as an internal standard.
Infrared spectra were recorded on a Nicolet Avatar 360 E.S.P. FT-infrared spectrometer.
Elemental analysis was performed by Atlantic Microlab, Inc., and determined values are
within 0.4% of theory (Supplemental Table 3). Thin-layer chromatography (TLC) was
performed using silica gel-coated GHLF plates (250 μm, 2.5 × 10 cm, Analtech, Inc.,
Newark, DE). Anhydrous solvents were purchased and stored under nitrogen over molecular
sieves. Medium pressure column chromatography was carried out using Silica gel 60,
0.040–0.063 mm, (230–400 mesh), Lancaster Synthesis.
3-Bromo-9-aminomethyl-9,10-dihydroanthracene hydrochloride (1b)
Tin(II) chloride dihydrate (1.06 g, 4.70 mmol) was added to a well stirred solution of 3-
bromo-9-nitromethyl-9,10-dihydroanthracene (8, 0.300 g, 0.940 mmol) in absolute EtOH (3
mL). The suspension was heated at 70 °C on an oil bath (5 h). The resulting bright yellow
solution was allowed to cool to room temperature and the solvent removed under reduced
pressure to provide a yellow oil. The oil was dissolved in EtOAc (10 mL), sat. NaHCO3
solution (5 mL) was added, the suspension was filtered and the filter cake was washed with
EtOAc (5 × 30 mL). The filtrate was collected, H2O (20 mL) was added and the mixture
was extracted with EtOAc. The EtOAc portion was washed with H2O (2 ×20 mL), brine (20
mL), dried (MgSO4) and concentrated under reduced pressure to provide a viscous yellow
oil. The resulting yellow oil was purified using medium pressure column chromatography
(CH2Cl2/MeOH, 9:1) to provide an opaque semisolid. The semisolid was dissolved in
EtOAc (10 mL) and ethereal HCl was added until no further precipitate formed. The
resulting suspension was filtered and washed with EtOAc to provide a white solid that was
recrystallized from MeOH/CHCl3 to provide 1b (0.10 g, 33%) as white crystals; mp 282–
284 °C dec. 1H NMR (DMSO-d6) δ 2.92–2.95 (d, J=8 Hz, 2H, CH2-NH3), 3.92–3.98 (d,
J=19 Hz, 1H, Ar-CH2-Ar), 4.12–4.19 (d, J=19 Hz, 1H, Ar-CH2-Ar), 4.28–4.34 (t, J=8 Hz,
1H, Ar-CH). Anal. (C15H14N • HCl • 0.25 H2O) C, H, N.
3-(3-Phenylpropyl)-9-aminomethyl-9,10-dihydroanthracene fumarate (1c)
Compound 1c was prepared from 15 in a manner analogous to 1e. The fumarate salt was
recrystallized from acetone/CHCl3 to provide 1c (0.042 g, 13%) as pale yellow crystals; mp
172–175 °C. 1H NMR (DMSO-d6) δ 1.83–1.93 (m, 2H, CH2), 2.56–2.63 (m, 4H, Ar-CH2),
2.82–2.85 (d, J=8 Hz, 2H, CH2-NH2), 3.83–3.89 (d, J=18 Hz, 1H, Ar-CH2-Ar), 4.06–4.12
(d, J=18 Hz, 1H, Ar-CH2-Ar), 4.12–4.17 (t, J=8 Hz, 1H, Ar-CH-Ar), 6.48 (s, 2H, Fumarate),
7.05–7.43 (brm, 12H, Ar-H). Anal. (C24H25N • C4H4O4•0.25 acetone) C, H, N.
3-n-Hexyl-9-aminomethyl-9,10-dihydroanthracene fumarate (1d)
2-Amino-1-(2-benzyl-4-n-hexylphenyl)-1-ethanol oxalate (20d, 0.350 g, 1.13 mmol) was
added to PPA (10.0 g) and the viscous mixture was stirred at room temperature by hand for
30 min. Water (100 mL) was slowly added and the mixture was made basic to pH 12 with
sat. NaHCO3. The aqueous solution was extracted with EtOAc (3 × 70 mL) and the organic
extracts were combined, dried (MgSO4) and concentrated under reduced pressure to provide
a brown oil. The oil was purified using medium pressure column chromatography (CH2Cl2/
MeOH, 9:1) to provide (0.100 g, 30%) as a pale orange oil. The oil was dissolved in
anhydrous acetone (20 mL) and anhydrous fumaric acid (0.030 g, 0.340 mmol) was added.
The mixture was heated until the solid dissolved and the mixture was then cooled and
filtered to provide 1d (0.070 g, 15%) as a white powder; mp 185–186 °C. 1H NMR (DMSO-
d6) δ 0.85–0.86 (s, 2H, CH3), 1.24 (brs, 6H, CH2), 1.55–1.62 (m, 2H, CH2), 2.52–2.57 (t,
J=8 Hz, 2H, CH3), 2.83–2.85 (d, J=8 Hz, 2H, CH2-NH2), 3.82–3.88 (d, J=18.5 Hz, 1H, Ar-
CH2-Ar), 4.06–4.12 (d, J=18.5 Hz, 1H, Ar-CH2-Ar), 4.12–4.19 (t, J=7 Hz, 1H, Ar-CH-Ar),
6.45 (s, 2H, Fumarate), 7.05–7.38 (brm, 7H, Ar-H). Anal. (C21H27N • C4H4O4 • 0.25 H2O)
C, H, N.
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2-Amino-1-[2-(3-methoxybenzyl)phenyl]-1-ethanol oxalate (20e, 0.130 g, 0.370 mmol) was
added to a well stirred solution of Eaton’s Reagent (20 mL) under N2. The mixture was
allowed to stir (1 h) and water (50 mL) was added. The suspension was made basic to pH 13
with 10% NaOH and extracted with EtOAc (3 × 35 mL). The extracts were combined, dried
(MgSO4) and concentrated under reduced pressure to provide a pale yellow oil (0.080 g,
0.330 mmol). The oil was dissolved in anhydrous 2-PrOH and fumaric acid (0.0420 g, 0.360
mmol) was added. The suspension was heated until all of the solid dissolved, allowed to
cool to room temperature and concentrated under reduced pressure. The solid residue was
then recrystallized (EtOAc/2-PrOH) to provide 1e (0.060 g, 45%); mp 195–197 °C. 1H
NMR (CD3OD) δ 2.79–2.82 (d/d, J=8 Hz, J=8 Hz, 2H, CH2-NH2), 3.58 (s, 3H, OCH3),
3.65–3.71 (d, J=19 Hz, 1H, Ar-CH2-Ar), 3.88–3.94 (d, J=19 Hz, 1H, Ar-CH2-Ar), 3.98–4.2
(t, J=8 Hz, 1H, Ar-CH-Ar), 6.47 (s, 2H, Fumarate), 6.62–6.64 (d, J=8 Hz, 1H, Ar-H), 6.72
(s, 1H, Ar-H), 7.04–7.12 (brm, 5H, Ar-H). 13C NMR (CD3OD) δ 36.49, 45.51, 46.08, 56.30,
114.05, 115.26, 128.46, 129.0, 129.16, 129.78, 129.98, 130.83, 136.79, 137.56, 138.51,
140.08. Anal. (C16H17NO • C4H4O4) C, H, N.
3-n-Pentyloxy-9-aminomethyl-9,10-dihydroanthracene fumarate (1f)
2-Amino-1-{2-[3-(n-pentyloxy)benzyl]phenyl}-1-ethanol oxalate 20f (0.500 g, 1.16 mmol)
was added to methanesulfonic acid (20 mL) under N2. The suspension was allowed to stir at
room temperature (2 h) and water (50 mL) was added. The suspension was made basic to pH
13 with 10% NaOH and extracted with EtOAc (3 × 50 mL). The combined extracts were
washed with water, brine, dried (MgSO4) and concentrated to provide a brown oil. The oil
was purified using medium pressure column chromatography (CH2Cl2\MeOH, 9:1) to
provide a yellow oil (0.190 g, 55%). The fumarate salt was prepared by adding fumaric acid
(0.750 g, 0.650 mmol) to the amine in 2-PrOH (30 mL). The suspension was heated until the
solid dissolved, cooled and filtered. The yellow solid was recrystallized from EtOAc/2-
PrOH to provide 1f (0.210 g, 44%) as pale yellow crystals; mp 178–180 °C. 1H NMR
(CD3OD) δ 0.70–0.75 (t, J=7 Hz, 3H, CH3), 1.16–1.26 (m, 4H, CH2), 1.50–1.57 (m, 2H,
CH2), 2.84–2.87 (d, J=8 Hz, 2H, CH2-NH2), 3.10–3.17 (m, 2H, CH2-O), 3.64–3.70 (d, J=19
Hz, 1H, Ar-CH2-Ar), 3.91–3.97 (d, J=19 Hz, 1H, Ar-CH2-Ar), 4.11–4.16 (t, J=8 Hz, 1H,
Ar-CH-Ar), 6.49 (s, 2H, fumarate), 6.59–6.62 (d, J=8 Hz, 1H, Ar-H), 6.72 (s, 1H, Ar-H),
7.04–7.23 (brm, 5H, Ar-H). 13C NMR (CD3OD) δ 14.95, 19.38, 24.08, 29.96, 30.68, 36.63,
45.51, 48.71, 48.99, 50.7, 53.28, 69.62, 114.59, 115.91, 128.5, 129.98, 130.86, 136.85,
137.8, 138.75, 140.30, 160.58, 171.87. Anal (C20H25NO • C4H4O4) C, H, N.
3-Hydroxy-9-aminomethyl-9,10-dihydroanthracene hydrobromide (1g)
The hydrobromide salt of 1e was prepared by adding ethereal HBr to 3-methoxy-9-
aminomethyl-9,10-dihydroanthracene in anhydrous Et2O until no further precipitate formed.
The suspension was filtered and the filter cake was washed with anhydrous Et2O. The white
powder was recrystallized from EtOAc\2-PrOH to provide 3-methoxy-9-aminomethyl-9,10-
dihydroanthracene hydrobromide as a white powder; mp 258–261 °C dec. A 1.0 M solution
of BBr3 in CH2Cl2 (1.0 mL, 0.960 mmol) was added under N2 in a dropwise manner to 3-
methoxy-9-aminomethyl-9,10-dihydroanthracene hydrobromide (0.100 g, 0.320 mmol) in
CHCl3 at −78 °C (dry ice/acetone). The suspension was allowed to warm to room
temperature over 2 h and was then allowed to stir for 5 h. The suspension was cooled to −78
°C, anhydrous MeOH (7 mL) was added and the suspension was allowed to warm to room
temperature. The suspension was concentrated under reduced pressure to provide a white
solid that was recrystallized from 2-PrOH\CHCl3 to provide 1g (0.430 g, 43%) as a white
powder; mp 278–281 °C dec. 1H NMR (DMSO-d6) δ 2.88–2.90 (d, J=6 Hz), 2H, CH2-
NH2), 3.77–3.84 (d, J=19 Hz, 1H, Ar-CH2-Ar), 4.03–4.10 (d, J=19 Hz, 1H, Ar-CH2-Ar),
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4.10–4.16 (t, J=6 Hz, 1H, Ar-CH-Ar), 6.64–6.67 (d, J=8 Hz, 1H, Ar-H), 6.77 (s. 1H, Ar-H),
7.17–7.39 (brm, 7H, Ar-H). Anal. (C15H15NO • HBr • 0.25 H2O) C, H, N.
3-n-Hexyl-6-methoxy-9-aminomethyl-9,10-dihydroanthracene fumarate (1h)
Compound 1h was prepared from 20h in a manner analogous to that of 1f. The resulting
yellow oil was purified using medium pressure column chromatography (CH2Cl2/MeOH,
9:1) to provide 1h (0.0580 g, 20%) as a white powder; mp 169–171 °C. 1H NMR (DMSO-
d6) δ 0.85–0.86 (t, J=6 Hz, 3H, CH3), 1.27 (m, 6H, CH2), 1.53–1.58 (m, 2H, CH2), 2.79–
2.84 (d, J=7 Hz, 2H, CH2-NH2), 3.74 (s, 3H, OCH3), 3.78–3.84 (d, J=19 Hz, 1H, Ar-CH2-
Ar), 4.04–4.08 (d, J=19 Hz, 1H, Ar-CH2-Ar), 4.08–4.12 (t, J=7 Hz, 1H, Ar-CH-Ar), 6.44 (s,
2H, Fumarate), 6.79–6.82 (d, J=8 Hz, 1H, Ar-H), 6.93 (s, 1H, Ar-H), 7.04–7.06 (d, J=8 Hz,
1H, Ar-H), 7.14 (s, 1H, Ar-H), 7.25–7.30 (m, 2H, Ar-H) Anal. (C22H30NO • C4H4O4) C, H,
N.
2-(4-Bromophenyl)-1-aminoethane hydrochloride (3b)
A 1.0 M solution of borane-THF complex (30.6 ml, 30.6 mmol) was added to 4-
bromophenyl acetonitrile (2.00 g, 10.2 mmol) in anhydrous THF (10 mL). The solution was
heated at reflux for 8 h. The solution was allowed to cool to room temperature, 6 M HCl (10
mL) was cautiously added and the solution was heated at reflux for 30 min. The solution
was allowed to cool to room temperature, 10% NaOH (45 mL) was added and the
suspension was extracted with CH2Cl2 (3 × 50 mL). The organic extracts were combined,
dried (MgSO4) and concentrated under reduced pressure to provide (1.50 g) of a colorless
oil. The oil was dissolved in anhydrous Et2O (50 mL) and ethereal HCl was added until no
more precipitate formed. The suspension was filtered and washed with anhydrous Et2O to
provide a white solid that was recrystallized from 2-PrOH to provide 3b (1.20 g, 58%) as
white needles; mp 239–241 °C dec. (Lit47 mp 240–243 °C) 1H NMR (CD3OD) δ 2.71–2.76
(m, 2H, CH2), 2.93–2.98 (m, 2H, CH2), 7.00–7.03 (d, J=8 Hz, 2H, Ar-H), 7.27–7.30 (d, J=8
Hz, 2H, Ar-H). 13C NMR (CD3OD) δ 34.43, 42.19, 132.37, 133.59
2-(4-n-Hexylphenyl)-1-aminoethane hydrochloride (3d)
Pd on charcoal (10%, 0.50 g) and concentrated sulfuric acid (0.300 g) were added to 26
(0.300 g, 1.40 mmol) in glacial acetic acid (5 mL). The mixture was hydrogenated (10 h) at
50 psi. The mixture was filtered through a Celite pad and the filter cake was washed with
glacial acetic acid (15 mL). The filtrate was concentrated under reduced pressure and made
basic to pH 10 with sat. NaHCO3. The suspension was extracted with EtOAc (3 × 40 mL)
and the organic extracts were combined, dried (MgSO4) and concentrated under reduced
pressure to provide (0.210 g, 1.00 mmol) of a pale yellow oil. The oil was dissolved in
anhydrous Et2O (25 mL) and a 1.0 M solution of HCl in Et2O (1 mL) was added. The
solution was cooled and filtered to provide a white powder. The powder was recrystallized
from 2-PrOH/Et2O to provide 3d (0.180 g, 53%) as white plates; mp 176–178 °C. (Lit.31
175–177 °C). 1H NMR (DMSO-d6) δ 0.85–0.87 (t, J=8 Hz, 3H, CH3), 1.12–1.14 (s, 6H,
CH2) 1.61–1.63 (m, 2H, CH2), 2.49–2.54 (t, J=7.7 Hz, 2H, Ar-CH2), 2.83–2.87 (m, 2H,
CH2), 2.95–2.99 (m, 2H, CH2), 7.13 (s, 4H, Ar-H). 13C NMR (DMSO-d6) δ 14.33, 22.44,
28.71, 31.34, 31.48, 32.91, 35.13, 40.27, 128.84, 134.37, 141.02.
2-(4-Bromophenyl)-2-phenyl-1-aminoethane hydrochloride (4b)
A 1.0 M solution of borane-THF complex (7.28 mL, 7.28 mmol) was added at room
temperature to a well stirred solution of 27 2-(4-bromophenyl)-2-phenylacetonitrile (0.500
g, 1.82 mmol) in anhydrous THF (5 mL). The solution was then heated at reflux (5 h) and
allowed to cool. A 6.0 M solution of HCl (7 mL) was cautiously added and the suspension
was heated at reflux (30 min). The suspension was allowed to cool, made basic with 10%
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NaOH (≈ 35 mL) and extracted with Et2O (3 × 35 mL). The organic extracts were
combined, dried (MgSO4) and concentrated under reduced pressure to provide an oily solid.
The solid was dissolved in anhydrous Et2O (40 mL) and ethereal HCl was added. The white
suspension was filtered and washed with anhydrous Et2O (10 mL). The white solid was
recrystallized from 2-PrOH to provide 4b (0.290 g, 51%) as white crystals; mp 216–218
°C. 1H NMR (DMSO-d6) δ 3.44–3.58 (m, 2H, CH2-NH2), 4.37–4.42 (t, J=8 Hz, 1H, CH),
7.23–7.53 (brm, 9H, Ar-H). Anal. (C14H14BrN • HCl) C, H, N.
2-(4-n-Hexylphenyl)-2-phenyl-1-aminoethane hydrochloride (4d)
A methanolic solution containing Raney nickel (≈ 0.500 g) was added to 2-(4-n-
hexylphenyl)-2-phenylacetonitrile (30, 0.400 g, 1.44 mmol) in anhydrous MeOH (20 mL)
and sat. NH3/MeOH solution (5 mL). The suspension was hydrogenated at 40 psi for 10 h.
The suspension was filtered through a Celite pad and the filter cake was washed with
anhydrous MeOH (25 mL). The filtrate was concentrated under reduced pressure to provide
a colorless oil. The oil was dissolved in anhydrous Et2O (35 mL) and ethereal HCl was
added until no further precipitate formed. The white suspension was filtered and washed
with anhydrous Et2O (10 mL). The white solid was recrystallized from 2-PrOH/Et2O to
provide 4d (0.200 g, 44%) as white crystals; mp 174–175 °C. 1H NMR (CD3OD) δ 0.65–
0.69 (t, J=8 Hz, 2H, CH3), 1.09 (s, 6H, CH2), 1.32–1.39 (m, 2H, CH2), 2.34–2.39 (t, J=7.7
Hz, 2H, CH2), 3.38–3.41 (d, J=7.8 Hz, 2H, CH2), 4.02–4.07 (t, J=8.25 Hz, 1H, CH), 6.95–
7.17 (brm, 9H, Ar-H). 13C NMR (DMSO-d6) δ 14.51, 20.41, 30.48, 33.17, 33.21, 37.02,
45.08, 50.87, 129.33, 129.42, 130.68, 130.73. Anal. (C20H27N • HCl): C, H, N.
1-Bromo-2-[(methoxymethoxy)methyl]benzene (5)
Chloromethylmethyl ether (1.61 g, 20.0 mmol) was added in a dropwise manner to a well
stirred solution of 2-bromobenzyl alcohol (3.00 g, 16.0 mmol) in N,N-diisopropylethylamine
(10 mL) at 0 °C under N2. The yellow solution was allowed to stir at 0 °C (2 h), allowed to
warm to room temperature and stirred (5 h). The solvent was removed under reduced
pressure to provide a yellow oil. The oil was dissolved in CHCl3 (30 mL) and washed with
water (3 × 75 mL). The organic extract was dried (MgSO4) and concentrated under reduced
pressure to provide a pale yellow oil that was purified using medium pressure column
chromatography (petroleum ether/acetone, 8:2) to provide 5 (2.79 g, 75%) as a colorless
oil. 1H NMR (CDCl3) δ 3.49 (s, 3H, CH3), 4.65 (s, 2H, CH2), 4.75 (s, 2H, CH2), 7.16–7.57
(brm, 4H, Ar-H). Compound 5 was used without further characterization in the preparation
of 6.
1-[1-(4-Bromophenyl)-2-nitroethyl]-2-[(methoxymethoxy)methyl]benzene (6)
A crystal of I2 was added to clean, dry magnesium turnings (0.160 g, 6.58 mmol) in
anhydrous THF (10 mL). 1-Bromo-2-[(methoxymethoxy)methyl]benzene (5, 1.58 g, 6.58
mmol) was slowly added (maintaining a gentle reflux) to the THF/Mg suspension and the
mixture was heated at reflux (≈ 45 min. or until most of the Mg was dissolved). The
suspension was allowed to cool to room temperature, the solvent was decanted from the
unreacted Mg turnings, and slowly added in a dropwise manner (not allowing the
temperature to rise above 10 °C) to an ice-cold well-stirred solution of trans-2-(4-
bromophenyl)-1-nitroethene (1.50 g, 6.58 mmol) in anhydrous THF (15 mL). After the
addition was complete the reaction was allowed to warm to room temperature (1 h) and
stirring was continued (10 h). HCl (1.0 M, 15 mL) was added and the suspension was
concentrated under reduced pressure. Water (25 mL) was added and the yellow suspension
was extracted with EtOAc (3 × 20 mL), washed with sat. NaHCO3 (40 mL) and brine (40
mL). The organic extracts were combined, dried (MgSO4) and concentrated under reduced
pressure to provide a viscous yellow oil. The resulting oil was purified by medium pressure
column chromatography (petroleum ether/acetone, 8:2) to provide 6 (1.00 g, 40%) as a
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viscous yellow oil. 1H-NMR (CDCl3): δ 3.45 (s, 3H, OCH3), 4.56–4.98 (brm, 6H, CH2),
5.29–5.35 (t, J=8 Hz, 1H, Ar-CH-Ar), 7.1–7.46 (brm, 9H, Ar-H). 13C-NMR (CDCl3) δ
44.07, 56.25, 68.06, 79.35, 96.32, 127.68, 128.39, 129.46, 130.05, 131.55, 132.66. IR (Film)
1556, 1376 cm−1. Compound 6 was used in the preparation of 7.
{2-[1-(4-Bromophenyl)-2-nitroethyl]phenyl}methanol (7)
Concentrated HCl (4 drops) was added to 1-[1-(4-bromophenyl)-2-nitroethyl]-2-
[(methoxymethoxy)methyl]benzene (6, 1.00 g, 2.63 mmol) in MeOH (15 mL). The reaction
mixture was heated in an oil bath at 65 °C (5 h). The solution was allowed to cool to room
temperature and concentrated under reduced pressure to provide a viscous yellow oil. The
oil was dissolved in EtOAc (20 mL), the suspension was made basic with sat. NaHCO3 (≈
50 mL) and the mixture was extracted with EtOAc (3 × 20 mL). The organic extracts were
combined, dried (MgSO4) and concentrated under reduced pressure to provide a viscous
yellow oil that was purified using medium pressure column chromatography (petroleum
ether/acetone, 8:2) to provide 7 (0.800 g, 90%) as a viscous yellow oil. 1H NMR (CDCl3) δ
4.64–4.92 (m, 2H, Ar-CH2-OH), 4.93–5.06 (m, 2H, CH2-NO2), 5.3–5.36 (t, J=8 Hz, 1H, Ar-
CH-Ar), 7.1–7.4 (brm, 8H, Ar-H). IR (Film) 3384, 1550, 1375 cm−1.
3-Bromo-9-nitromethyl-9,10-dihydroanthracene (8)
PPA (5ml) was added to {2-[1-(4-Bromophenyl)-2-nitroethyl]phenyl}methanol (7, 1.02 g,
3.04 mmol) and the viscous mixture was stirred by hand and heated on an oil bath at 65 °C
(30 min). After the reaction was complete, ice (40.0 g) was added to the white/brown
semisolid and the solution was made basic to pH 12 with sat. NaHCO3 solution. The
suspension was extracted with EtOAc (3 × 25 mL) and the organic extracts were combined,
dried (MgSO4) and concentrated under reduced pressure to provide a brown semisolid
(0.540 g). The crude solid was then recrystallized from methanol to provide 8 (0.480 g,
49%) as pale yellow crystals; mp 113–114 °C. 1H NMR (CDCl3): δ 3.80–3.95 (d, J=19 Hz,
1H, CH2), 4.07–4.13 (d, J=19 Hz, 1H, Ar-CH2-Ar), 4.37–4.49 (m, 2H, CH2-NO2) 4.76–4.82
(t, J=9 Hz, 1H, CH), 7.15–7.39 (brm, 7H, Ar-H). 13C NMR (CDCl3) δ 35.22, 45.5, 80.15,
122.27, 127.85, 128.56, 128.66, 128.85, 130.24, 130.61, 131.75, 133.91, 134.28, 136.05,
139.17. IR (KBr) 1537, 1382, cm−1.
4-Bromo-2-(bromomethyl)benzonitrile (9)
NBS (3.49 g, 19.6 mmol) was added to 4-bromo-2-methylbenzonitrile (3.50 g, 17.9 mmol)
in CCl4 (25 mL) under N2. The reaction was slowly warmed with an IR lamp and heated at
reflux (6 h). The suspension was cooled, filtered and the filtrate was concentrated under
reduced pressure to provide an oily solid. The oily solid was purified using medium pressure
column chromatography (petroleum ether/acetone 9:1) to provide a white solid that was
recrystallized (toluene/petroleum ether) to provide 9 (3.45 g, 70%) as white needles; mp 88–
91 °C. 1H NMR (CDCl3) δ 4.55 (s, 2H, CH2-Br), 7.54–7.58 (m, 2H, Ar-H), 7.73 (s, 1H, Ar-
H). 13C NMR (CDCl3) δ 28.78, 128.72, 132.90, 133.81, 134.26, 134.78, 142. 67. The
product was used in the preparation of 10.
2-Benzyl-4-bromobenzonitrile (10)
4-Bromo-2-(bromomethyl)benzonitrile (9, 3.25 g, 11.82 mmol) was added under N2 to
AlCl3 (3.14 g, 23.6 mmol) in anhydrous benzene (30 mL) at 0 °C. The reaction mixture was
allowed to warm to room temperature and heated at reflux (45 min). The reaction was
allowed to cool, poured onto ice (50.0 g) and made acidic to pH 2 with 5% HCl. The
suspension was extracted with CH2Cl2 (3 × 75 mL) and the combined extracts were washed
with water, brine, dried (MgSO4) and concentrated under reduced pressure to provide a
white solid. The white solid was recrystallized from toluene/petroleum ether to provide 10
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(3.10 g, 96%) as white crystals; mp 73–75 °C. 1H NMR (CDCl3) δ 4.13 (s, 2H, Ar-CH2-Ar),
7.07–7.50 (brm, 8H, Ar-H). 13C NMR (CDCl3) δ 40.56, 127.63, 129.49, 129.55, 130.88,
133.82, 134.55. Compound 10 was used without further characterization in the preparation
of 11.
2-Benzyl-4-bromobenzoic acid (11)
2-Benzyl-4-bromobenzonitrile (10, 0.90 g, 3.31 mmol) was added to KOH (1.15 g, 24.2
mmol) in ethylene glycol (7 mL) and water (0.5 mL). The solution was heated at reflux (3
h), allowed to cool to room temperature and made acidic to pH 2 with 5% HCl. The
suspension was extracted with CHCl3 (3 × 50 mL) and the extracts were washed with water,
brine, dried (MgSO4) and concentrated under reduced pressure to provide a white solid. The
solid was recrystallized from formic acid/acetic acid to provide 11 (0.950 g, 100%) as white
crystals; mp 131–134 °C. 1H NMR (DMSO-d6) δ 4.36 (s, 2H, Ar-CH2-Ar), 6.67 (s, 1H, Ar-
H), 7.01–7.04 (d, J=8 Hz, 1H, Ar-H), 7.16–7.78 (brm, 6H, Ar-H).
2-Benzyl-4-bromobenzyl alcohol (12)
Compound 12 was prepared from 11 in a manner analogous to that of 21. The resulting oil
(1.01 g, 96 %) was used in the next step without further purification.
2-Benzyl-4-bromobenzaldehyde (13)
Compound 13 was prepared from 12 in a manner analogous to that of 19d. The resulting oil
was purified using medium pressure column chromatography (petroleum ether/acetone, 9:1)
to provide 13 (0.750 g, 75%) as a colorless oil. 1H NMR (CDCl3) δ 4.27 (s, 2H, Ar-CH2-
Ar), 7.02–7.29 (brm, 7H, Ar-H), 7.69–7.74 (d, J=6 Hz, 1H, Ar-H), 10.11 (s, 1H, COH).
2-Benzyl-4-(3-phenylpropyl)benzaldehyde (14)
A 0.5 M solution of 9-BBN in THF (8 mL, 4.00 mmol) was added under N2 in a dropwise
manner to a solution of allylbenzene (0.470 g, 4.01 mmol) in anhydrous THF (2.5 mL) at 0
°C. The mixture was then allowed to stir for 12 h at room temperature. 2-Benzyl-4-
bromobenzaldehyde (13, 1.00 g, 3.34 mmol) in THF (12 mL), PdCl2(dppf) (0.080 g, 0.100
mmol) and NaOH (3 M, 3.34 mL) were then added to the flask containing the 9-
phenylpropyl-9-BBN. The mixture was heated at reflux (12 h), allowed to cool to room
temperature and water (20 mL) was added. The suspension was extracted with EtOAc (3 ×
50 mL) and the combined extracts were washed with water, brine, dried (MgSO4) and
concentrated under reduced pressure. The resulting brown oil was purified using medium
pressure column chromatography (petroleum ether/acetone, 9:1) to provide 14 (0.700 g,
66%) as a colorless oil. 1H NMR (CDCl3) δ 1.90–2.00m (m, 2H, CH2), 2.60–2.68 (m, 4H,
Ar-CH2), 4.40 (s, 2H, Ar-CH2-Ar), 7.06–7.30 (brm, 12H, Ar-H), 7.76–7.79 (d, J=8Hz, 1H,
Ar-H), 10.17 (s, 1H, COH). 13C NMR (CDCl3) δ 33.00, 35.90, 36.03, 38.62, 126.50, 126.80,
127.70, 128.97, 129.13, 129.29, 130.23, 132.49, 132.98, 141.13, 142.36, 143.60, 149.73,
192.55.
2-Amino-1-[2-benzyl-4-(3-n-phenylpropyl)phenyl]-1-ethanol oxalate (15)
Compound 15 was prepared from 14 in a manner analogous to that of 20d. The oxalate salt
was recrystallized from 2-PrOH to provide 15 (0.630 g, 64%) as a white powder; mp 168–
170 °C. 1H NMR (DMSO-d6) δ 1.78–1.88 (m, 2H, CH2), 2.45–2.57 (m, 4H, CH2-Ar), 2.70–
2.79 (m, 2H, CH2-NH2), 3.92–3.97 (d, J=16 Hz, 1H, Ar-CH2-Ar), 4.02–4.07 (d, J=16 Hz,
1H, Ar-CH2-Ar), 5.05–5.08 (d, J=9 Hz, CH-OH), 6.96 (s, 1H, Ar-H), 7.15–7.53 (brm, 12H,
Ar-H). Anal (C24H27NO • C2H2O4) C, H, N.
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A solution of 4-n-hexylbenzoyl chloride (3.00 g, 13.3 mmol) in CH2Cl2 (6 mL) was added
under N2 to 2-amino-2-methyl-1-propanol (2.49 g, 27.9 mmol) in CH2Cl2 (6 mL) at such a
rate as to maintain a temperature of 0 °C. The suspension was allowed to stir for 4 h and was
filtered. The filter cake was washed with CH2Cl2 (2 × 20 mL) and the filtrate was washed
with 3N HCl (100 mL) and water (100 mL). The solvent was removed under reduced
pressure to provide (3.60 g, 97%) a yellow oil. Thionyl chloride (1.83 g, 15.31 mmol) was
added slowly to the crude 4-n-hexyl-N-(2-hydroxy-1,1-dimethylethyl) benzamide (3.60 g,
13.0 mmol) in anhydrous toluene (25 mL). The solution was stirred at room temperature (10
h), poured into water (30 mL), made basic to pH 10 with sat. NaHCO3 and extracted with
EtOAc (3 × 40 mL). The extracts were combined, dried (MgSO4) and concentrated under
reduced pressure to provide a pale orange oil. The oil was purified by Kuhgelrohr bulb to
bulb distillation (bp 141 °C @ 0.10 mm Hg) to provide 16d (3.33 g, 98%) as a colorless
oil. 1H NMR (CDCl3) δ 0.85–0.89 (t, J=7 Hz, 3H, CH3), 1.28 (s, 6H, CH2), 1.37 (s, 6H,
CH3), 1.53–1.62 (m, 2H, CH2), 2.6–2.65 (t, J=7 Hz, 2H, Ar-CH2), 4.09 (s, 2H, CH2-O),
7.19–7.22 (d, J=8 Hz, 2H, Ar-H), 7.83 (d, J=8 Hz, 2H, Ar-H). 13C NMR (CDCl3) δ 14.64,
23.14, 28.99, 29.43, 31.76, 32.23, 36.48, 79.59, 128.74, 128.92, 147.09. IR (Film) 1655
cm−1.
5-n-Hexyl-3-phenyl-1,3-dihydro-1-isobenzofuranone (17d)
A well stirred solution of 2-(4-n-hexylphenyl)-4,4-dimethyl-2-oxazoline (16d, 1.00 g, 3.85
mmol) in anhydrous THF (5 mL) was cooled to −78 °C (dry ice/acetone) under N2. A 2.5 M
solution of n-butyl lithium in cyclohexane (1.77 mL, 4.43 mmol) was added slowly to the
solution so as to maintain the temperature at −78 °C. The solution was allowed to warm to
room temperature and stirred (1 h). The red solution was then cooled to 0 °C and a solution
of benzaldehyde (0.410 g, 3.85 mmol) in anhydrous THF (2 mL) was added over 30 min.
The reaction mixture was allowed to stir for 5 h at room temperature and H2O (20 mL) was
added. The mixture was extracted with EtOAc (3 × 30 mL). The combined fractions were
dried (MgSO4) and concentrated under reduced pressure to provide a yellow oil. HCl (5%,
25 mL) was added to the oil and the suspension was heated at reflux (10 h). The suspension
was allowed to cool and extracted with EtOAc (3 × 40 mL). The combined extracts were
dried (MgSO4) and concentrated under reduced pressure to provide an orange oil that was
purified by medium pressure column chromatography (petroleum ether/acetone, 9:1) to
provide 17d (0.910 g, 80%) as a colorless oil that solidified on standing. The solid was
recrystallized from EtOAc/petroleum ether; mp 69–70 °C. 1H NMR (CDCl3) δ 0.85 (s, 3H,
CH3), 1.28 (s, 6H, CH2), 1.53–1.62 (m, 2H, CH2), 2.6–2.65 (s, 2H, Ar-CH2), 6.35 (s, 1H,
Ar-CH-Ar), 7.26–7.86 (brm, 8H, Ar-H). IR (KBr) 1743 cm−1.
3-(3-Methoxyphenyl)-1,3-dihydro-1-isobenzofuranone (17e)
Compound 17e was prepared from 3-methoxybenzaldehyde and 2-phenyl-4,4-dimethyl-2-
oxazoline in a manner analogous to 17d. The resulting yellow solid was recrystallized from
EtOH/MeOH to provide 17e (5.60 g, 81%) as yellow needles; mp 112–114 °C. 1H NMR
(CDCl3) δ 3.77 (s, 3H, OCH3), 6.37 (s, 1H, Ar-CH-Ar), 6.78–6.91 (m, 3H, Ar-H), 7.27–7.96
(brm, 5H, Ar-H). 13C NMR (CDCl3) δ 54.89, 82.08, 111.98, 114.20, 118.65, 122.41,
125.02, 125.20, 128.94, 129.63, 133.90, 137.50, 149.16, 159.57, 170.06.
3-[3-(n-Pentyloxy)phenyl]-1,3-dihydro-1-isobenzofuranone (17f)
Compound 17f was prepared from 21 (3-n-pentyloxybenzaldehyde) and 2-phenyl-4,4-
dimethyl-2-oxazoline in a manner analogous to 17d. The resulting yellow solid was
recrystallized from toluene/petroleum ether to provide 17f (4.78 g, 55%) as yellow needles;
mp 94–96 °C. 1H NMR (CDCl3) δ 0.89–0.94 (t, J=7 Hz, 3H, CH3), 1.3–1.46 (m, 4H, CH2),
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1.70–1.79 (m, 2H, CH2), 3.88–3.93 (t, J=7 Hz, 3H, CH2-O), 6.36 (s, 1H, Ar-CH-Ar), 6.77
(s, 1H, Ar-H), 6.85–6.90 (m, 2H, Ar-H) 7.25–7.67 (brm, 4H, Ar-H), 7.94–7.96 (d, J=8 Hz,
1H, Ar-H). 13C NMR (CDCl3) δ 14.56, 23.0, 28.71, 29.45, 68.63, 83.15, 113.55, 115.65,
119.46, 123.42, 126.04, 126.19, 129.91, 130.57, 134.88, 138.42, 150.23, 160.16.
5-n-Hexyl-3-(3-methoxyphenyl)-1,3-dihydro-1-isobenzofuranone (17h)
Compound 17h was prepared from 16d (2-(4-n-hexylphenyl)-4,4-dimethyl-2-oxazoline) and
3-methoxybenzaldehyde in a manner analogous to that of 17d. The resulting orange oil was
purified using medium pressure column chromatography (petroleum ether/acetone, 9:1) to
provide 17h (4.82 g, 77%) as a yellow oil. 1H NMR (CDCl3) δ 0.83–0.87 (t, J=6 Hz, 3H,
CH3), 1.28 (m, 6H, CH2), 1.57–1.60 (m, 2H, CH2), 2.64–2.69 (t, J=8 Hz, 2H, CH2-Ar), 3.77
(s, 3H, OCH3), 6.31 (s, 1H, Ar-CH-Ar), 6.79–6.90 (m, 3H, Ar-H), 7.12 (s, 1H, Ar-H), 7.27–
7.36 (m, 2H, Ar-H), 7.82–7.85 (d, J=8 Hz, 1H, Ar-H). 13C NMR (CDCl3) δ 14.59, 23.08,
29.44, 31.74, 32.12, 36.93, 55.88, 82.91, 112.99, 115.14, 119.73, 122.99, 123.68, 126.00,
130.52, 130.58, 138.78, 150.69, 151.24, 160.62. IR (Film) 1772 cm−1.
2-Benzyl-4-n-hexylbenzoic acid (18d)
Five drops of HClO4 (70% in water), 10% Pd/C (0.100 g) and 5-n-hexyl-3-phenyl-1,3-
dihydro-1-isobenzofuranone 17d (0.400 g, 1.36 mmol) was hydrogenated in 2-PrOH (11
mL) at 55 psi for 12 h. The suspension was filtered through a Celite pad and concentrated
under reduced pressure. The resulting oil was dissolved in CHCl3 (50 mL) and extracted
with 10% NaOH (40 mL). The aqueous layer was made acidic to pH 3 with 5% HCl and
extracted with CH3Cl (3 × 50 mL). The organic extracts were combined, dried (MgSO4) and
concentrated under reduced pressure to provide a white solid. The solid was recrystallized
from formic acid/acetic acid to provide 18d (0.300 g, 74%) as white needles; mp 67–68
°C. 1H NMR (CDCl3) δ 0.84–0.89 (t, J=7 Hz, 2H, CH3), 1.27 (brs, 6H, CH2), 1.53–1.58 (m,
2H, CH2), 2.56–2.61 (t, J=6 Hz, 2H, CH3), 4.43 (s, 2H, Ar-CH2-Ar), 7.03–7.28 (brm, 7H,
Ar-H), 7.98–8.01 (d, J=8 Hz,1H, Ar-H). 13C NMR (CDCl3) δ 14.65, 23.15, 29.47, 31.51,
32.20, 36.43, 40.23, 126.42, 127.04, 128.84, 129.52, 132.56, 132.65, 149.22, 173.23. IR
(KBr) 2924, 1687 cm−1.
2-(3-Methoxybenzyl)benzoic acid (18e)
Compound 18e was prepared from 17e in a manner analogous to 18d. The resulting white
solid was recrystallized from formic acid/acetic acid to provide 18e (1.81 g, 89%) as white
needles; mp 95–96 °C. 1H NMR (CDCl3) δ 3.77 (s, 3H, OCH3), 4.46 (s, 2H, Ar-CH2-Ar),
6.75–6.77 (d, J=7 Hz, 1H, Ar-H), 6.8 (s, 1H, Ar-H), 7.18–7.5 (brm, 5H, Ar-H), 8.08–8.10
(d, J=7.8 Hz, 1H, Ar-H). 13C NMR (CDCl3) 40.19, 55.67, 111.92, 115.48, 122.13, 126.97,
129.87, 132.29, 133.62, 142.89, 143.89, 173.79.
2-[3-(n-Pentyloxy)benzyl]benzoic acid (18f)
Compound 18f was prepared from 17f in a manner analogous to that of 18d. The resulting
white solid was recrystallized from formic acid/acetic acid to provide 18f (4.18 g, 96%) as
white needles; mp 89–91 °C. 1H NMR (DMSO-d6) δ 0.85–0.89 (t, J=6 Hz, 3H, CH3), 1.27–
1.33 (m, 4H, CH2), 1.61–1.68 (m, 2H, CH2), 3.84–3.88 (t, J=6 Hz, 2H, CH2-O), 4.30 (s, 2H,
Ar-CH2-Ar), 6.69 (m, 2H, Ar-H), 6.71 (s, 1H, Ar-H), 7.11–7.48 (brm, 4H, Ar-H), 7.79–7.82
(d, J=8 Hz, 1H, Ar-H). 13C NMR (DMSO-d6) 14.26, 22.26, 28.09, 28.76, 38.74, 67.53,
111.83, 115.44, 121.18, 126.65, 129.59, 130.57, 131.06, 131.70, 132.07, 141.80, 143.03,
159.03, 169.22.
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Compound 18h was prepared from 17h in a manner analogous to that of 18d. The resulting
yellow semisolid was recrystallized from formic acid/acetic acid to provide 18h (2.21 g,
84%) as a white powder; mp 58–60 °C. 1H NMR (CDCl3) δ 0.86–0.91 (t, J=6 Hz, 3H, CH3),
1.29 (m, 6H, CH2), 1.55–1.62 (m, 2H, CH2), 2.58–2.63 (t, J=8 Hz, 2H, CH2-Ar), 3.76 (s,
3H, OCH3), 4.43, (s, 2H, Ar-CH2-Ar), 6.73–6.78 (m, 3H, Ar-H) 7.05–7.21 (brm, 3H, Ar-H),
7.99–8.0 (d, J=8 Hz, 1H, Ar-H). 13C NMR (CDCl3) δ 14.64, 23.14, 29.77, 31.50, 32.21,
36.43, 40.22, 55.63, 111.83, 115.32, 122.01, 126.23, 127.06, 129.75, 132.55, 132.60,
143.16, 143.84, 149.23, 160.00, 173.44.
2-Benzyl-4-n-hexylbenzaldehyde (19d)
A solution of 2-benzyl-4-n-hexylbenzyl alcohol (21, 0.400 g, 1.42 mmol) in anhydrous
CH2Cl2 (5 mL) was added over 30 min at room temperature to a well stirred suspension of
PCC (0.460 g, 2.13 mmol) and Celite (1.0 g in 50 mL CH2Cl2). The solution was allowed to
stir at room temperature for 2 h, anhydrous Et2O (25 mL) was added and the dark brown
suspension was filtered through a Florisil column. The solution was concentrated under
reduced pressure to provide 19d (0.320 g, 80%) as a colorless oil. The product was used
without further purification. 1H NMR (CDCl3) δ 0.85–0.87 (t, J=7 Hz, 2H, CH3), 1.28 (brs,
6H, CH2), 1.55–1.60 (m, 2H, CH2), 2.60–2.65 (t, J=8 Hz, 2H, CH3), 4.14 (s, 2H, Ar-CH2-
Ar), 7.07–7.29 (brm, 7H, Ar-H), 7.75–7.78 (d, J=8 Hz, 1H, Ar-H), 10.17 (s, 1H, COH). 13C
NMR (CDCl3) δ 14.65, 23.15, 29.50, 31.52, 32.21, 36.66, 38.65, 126.76, 127.68, 129.08,
129.28, 132.47, 132.93, 140.85, 143.48, 150.55, 192.59. IR (Film) 1693 cm−1.
2-(3-Methoxybenzyl)benzaldehyde (19e)
Compound 19e was prepared from 23 in a manner analogous to that of 19d. The resulting oil
was purified using medium pressure column chromatography (petroleum ether/acetone, 8:2)
to provide 19e (0.490 g, 98%) as a pale yellow oil. 1H NMR (CDCl3) δ 3.75 (s, 3H, OCH3),
4.42 (s, 2H, Ar-CH2-Ar), 6.68 (s, 1H, Ar-H), 6.72–6.75 (d, J=8.2 Hz, 1H, Ar-H), 7.17–7.53
(brm, 5H, Ar-H), 7.84–7.85 (d, J=3 Hz, 1H, Ar-H), 10.24 (s, 1H, COH). 13C NMR (CDCl3)
38.59, 55.69, 111.96, 115.34, 121.77, 127.60, 130.10, 132.21, 132.56, 134.50, 192.95. IR
(Film) 1699 cm−1.
2-[3-(n-Pentyloxy)benzyl]benzaldehyde (19f)
Compound 19f was prepared from 24 in a manner analogous to that of 19d. The resulting oil
was purified using medium pressure column chromatography (petroleum ether/acetone, 8:2)
to provide 19f (3.56 g, 100%) as a pale yellow oil. 1H NMR (CDCl3) δ 0.85–0.93 (t, J=7 Hz,
3H, CH3), 1.32–1.42 (m, 4H, CH2), 1.69–1.76 (m, 2H, CH2), 3.86–3.90 (t, J=7 Hz, 2H,
CH2-O), 4.40 (s, 2H, Ar-CH2-Ar), 6.68–6.73 (m, 3H, Ar-H), 7.14–7.54 (brm, 4H, Ar-H),
7.83–7.87 (d, J=8 Hz, 1H, Ar-H), 10.24 (s, 1H, COH).
4-n-Hexyl-2-(3-methoxybenzyl)benzaldehyde (19h)
Compound 19h was prepared from 25 in manner analogous to that of 19d. The resulting
brown oil was purified using medium pressure column chromatography (petroleum ether/
acetone, 9:1) to provide 19h (1.98 g, 92 %) as a pale yellow oil. 1H NMR (CDCl3) δ 0.85–
0.89 (t, J=6 Hz, 3H, CH3), 1.26–1.29 (m, 6H, CH2), 1.58–1.63 (m, 2H, CH2), 2.59–2.65 (t,
J=8 Hz, 2H, CH2-Ar), 3.75 (s, 3H, OCH3), 4.39 (s, 2H, Ar-CH2-Ar), 6.68–6.74 (m, 3H, Ar-
H), 7.07–7.23 (m, 3H, Ar-H), 7.75–7.78 (d, J=8 Hz, 1H, Ar-H), 10.17 (s, 1H, COH). 13C
NMR (CDCl3) δ 14.62, 23.12, 29.48, 31.50, 32.20, 36.64, 38.62, 55.66, 111.89, 115.25,
121.70, 127.69, 130.03, 132.44, 132.87, 142.68, 143.27, 150.41, 160.0, 192.54. IR (Film)
1700 cm−1.
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Trimethylsilyl cyanide (0.270 g, 2.78 mmol) was added to a suspension of 2-benzyl-4-n-
hexylbenzaldehyde (19d, 0.650 g, 2.32 mmol) and ZnI2 (catalytic amount) in anhydrous
CH2Cl2 (3 mL). The solution was allowed to stir at room temperature (3 h) and heated at
reflux (1 h). The solution was allowed to cool to room temperature and concentrated under
reduced pressure to give a pale yellow oil. The oil in anhydrous THF (5 mL) was added
under N2 to a suspension of LiAlH4 (0.260 g, 6.85 mmol) in anhydrous THF (10 mL) at 0
°C. The solution was warmed to room temperature, and heated at reflux (5 h). The solution
allowed to cool to room temperature and water, (0.25 mL), 10% NaOH (0.25 mL) and Celite
(1.5 g) were added. The suspension was filtered through a sintered glass filter and the filter
cake was washed with CH2Cl2 (75 mL). The filtrate was dried (MgSO4) and concentrated
under reduced pressure to provide (0.460 g) a colorless oil. The oil was dissolved in
anhydrous acetone (20 mL) and oxalic acid (0.130 g, 1.38 mmol) was added. The solution
was heated until the solid dissolved and the solution was cooled and filtered to provide 20d
(0.420 g, 45%) as white crystals; mp 164–166 °C. 1H NMR (DMSO-d6) δ 0.85–0.87 (s, 2H,
CH3), 1.28 (brs, 6H, CH2), 1.55–1.60 (brs, 2H, CH2), 2.48–2.53 (t, J=6 Hz, 2H, CH3), 2.69–
2.78 (m, 2H, CH2-NH2), 3.91–3.96 (d, J=16 Hz, 1H, Ar-CH2-Ar), 4.00–4.06 (d, J=16 Hz,
1H, Ar-CH2-Ar), 5.03–5.06 (d, J=8.5 Hz, 1H, CH-OH), 6.97–7.44 (brm, 8H, Ar-H). 13C
NMR (DMSO-d6) δ 14.67, 23.20, 29.60, 31.93, 32.27, 36.14, 38.79, 46.38, 67.06, 126.55,
126.91, 127.67, 129.01, 129.46, 131.11, 137.95, 136.09, 141.01, 143.45.
2-Amino-1-[2-(3-methoxybenzyl)phenyl]-1-ethanol oxalate (20e)
Compound 20e was prepared from 19e in a manner analogous to 20d. The oxalate salt was
prepared and recrystallized from 2-PrOH to provide 20e (0.130 g, 33%) as a white powder;
mp 159–161 °C. 1H NMR (CD3OD) δ 2.54–2.62 (m, 2H, CH2-NH2), 3.51 (s, 3H, OCH3),
3.86 (s, 2H, Ar-CH2-Ar), 4.93–4.98 (d, J=9 Hz, 1H, Ar-CH-OH), 6.47–6.54 (m, 2H, Ar-H),
6.94–7.10 (brm, 5H, Ar-H), 7.38–7.40 (m, 1H, Ar-H). 13C NMR (CD3OD) δ 39.65, 47.19,
56.11, 67.91, 113.02, 116.15, 122.61, 127.99, 128.75, 129.77, 131.13, 132.50, 139.18,
141.31, 144.10, 166.95.
2-Amino-1-{2-[3-(n-pentyloxy)benzyl]phenyl}-1-ethanol oxalate (20f)
Compound 20f was prepared from 19f in a manner analogous to that of 20d. The oxalate salt
was prepared and recrystallized from 2-PrOH to provide 20f (2.68 g, 51%) as a white
powder; mp 140–142 °C. 1H NMR (DMSO-d6) δ 0.85–0.90 (t, J=7 Hz, 3H, CH3), 1.13–1.18
(m, 2H, CH2), 1.28–1.34 (m, 2H, CH2), 2.7–2.84 (m, 2H, CH2-NH2), 3.83–3.92 (t, J= 7 Hz,
2H, CH2-O), 3.93–3.98 (d, J=16 Hz, 1H, Ar-CH2-Ar), 4.02–4.07 (s, J=16 Hz, 1H, Ar-CH2-
Ar), 5.2–5.23 (d, J=8 Hz, 1H, CH-OH), 6.66–6.78 (m, 3H, Ar-H), 7.14–7.35 (brm, 4H, Ar-
H), 7.53–7.67 (d, J=8 Hz, 1H, Ar-H).
2-Amino-1-[4-n-hexyl-2-(3-methoxybenzyl)phenyl]-1-ethanol fumarate (20h)
Compound 20h was prepared from 19h in a manner in a manner analogous to that of 20d.
The fumarate salt was recrystallized from EtOAc/2-PrOH to provide 20h (0.510 g, 46%) as
a white powder; mp 162–164 °C. 1H NMR (DMSO-d6) δ 0.81–0.85 (t, J=6 Hz, 3H, CH3),
1.24 (m, 6H, CH2), 1.49–1.53 (m, 2H, CH2), 2.64–2.83 (m, 2H, CH2-NH2), 3.69 (s, 3H,
OCH3), 3.86–3.91 (d, J=16 Hz, 1H, Ar-CH2-Ar), 3.98–4.03 (d, J=16 Hz, 1H, Ar-CH2-Ar),
5.05–5.08 (d, J=10 Hz, 1H, CH-OH), 6.46 (s, 2H, Fumarate), 6.72–6.74 (m, 3H, Ar-H), 6.96
(s, 1H, Ar-H), 7.06–7.19 (brm, 2H, Ar-H), 7.41–7.43 (d, J=8 Hz, 1H, Ar-H). 13C NMR
(DMSO-d6) δ 14.31, 22.43, 28.60, 31.25, 31.46, 35.10, 37.46, 45.97, 55.22, 66.21, 111.59,
114.80, 121.23, 126.54, 126.87, 129.66, 130.54, 135.68, 137.21, 138.04, 141.82, 142.62,
159.66, 168.84.
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KOH (3.25 g, 49.1 mmol) was added to 3-hydroxybenzaldehyde (5.00 g, 40.9 mmol) in
absolute EtOH (125 mL). The mixture was allowed to stir for 30 min at room temperature
and 1-bromopentane (6.80 g, 45.0 mmol) was added. The reaction mixture was heated at
reflux (12 h) and the suspension was allowed to cool to room temperature, water (75 mL)
was added and the solution was extracted with Et2O (3 × 75 mL). The combined extracts
were washed with water, brine, dried (MgSO4) and concentrated under reduced pressure to
provide a pale orange oil. The oil was purified using medium pressure column
chromatography (petroleum ether/acetone, 9:1) to provide 21 (5.82 g, 74%) as an orange
oil. 1H NMR (CDCl3) δ 0.91–0.96 (t, J=7 Hz, 3H, CH3), 1.31–1.48 (m, 4H, CH2), 1.17–1.85
(m, 2H, CH2), 3.98–4.03 (t, J=6 Hz, 2H, CH2-O), 7.15–7.17 (m, 1H, Ar-H), 7.37–7.44 (brm,
3H, Ar-H), 9.96 (s, 1H, COH). 13C NMR (CDCl3) δ 14.56, 22.98, 28.71, 29.38, 68.86,
113.35, 122.50.123.82, 130.53, 138.34, 159.98, 192.75.
2-Benzyl-4-n-hexylbenzyl alcohol (22)
A 1.0 M solution of borane-THF complex (8 mL, 8 mmol) was added under N2 to a well
stirred solution of 2-benzyl-4-n-hexylbenzoic acid (18d, 0.600 g, 2.00 mmol) at 0 °C. The
solution was heated at reflux (5 h) and allowed to cool. HCl 6.0 M (5 mL) was added
cautiously and the mixture was again heated at reflux (30 min). The solution was allowed to
cool to room temperature, made basic with 15% NaOH (≈ 30 mL) and extracted with EtOAc
(3 × 45 mL). The organic extracts were combined, dried (MgSO4) and concentrated under
reduced pressure to provide 22 (0.450 g, 79%) as a colorless oil. The product was used
without further purification. 1H NMR (CDCl3) δ 0.85–0.89 (t, J=6 Hz, 2H, CH3), 1.28 (brs,
6H, CH2), 1.53–1.60 (m, 2H, CH2), 2.54–2.59 (t, J=8 Hz, 2H, CH3), 4.06 (s, 2H, CH2), 4.58
(s, 2H, CH2), 7.0–7.30 (brm, 8H, Ar-H). 13C NMR (CDCl3) δ 14.69, 23.20, 29.56, 32.03,
32.29, 36.19, 39.16, 63.72, 126.66, 127.37, 129.08, 129.17, 129.28, 131.48, 136.71, 138.52,
141.12, 143.42. IR (Film) 3334 cm−1.
2-(3-Methoxybenzyl)benzyl alcohol (23)
Compound 23 was prepared from 18e in a manner analogous to that of 22. The resulting oil
was purified using medium pressure column chromatography (petroleum ether/acetone, 8:2)
to provide 23 (0.540 g, 75%) as a colorless oil. 1H NMR (CDCl3) δ 3.76 (s, 3H, OCH3),
4.07 (s, 2H, Ar-CH2-OH), 4.65 (s, 2H, Ar-CH2-Ar), 6.7–6.76 (brm, 2H, Ar-H), 7.18–7.41
(brm, 6H, Ar-H). 13C NMR (CDCl3) 39.06, 55.70, 63.79, 111.87, 115.21, 121.66, 127.44,
128.57, 128.96, 130.08, 131.15, 138.94, 139.41, 142.77, 159.88. IR (Film) 3340 cm−1.
2-[3-(n-Pentyloxy)benzyl]benzyl alcohol (24)
Compound 24 was prepared from 18f in a manner analogous to that of 22. The resulting oil
was purified using medium pressure column chromatography (petroleum ether/acetone, 8:2)
to provide 24 (3.58 g, 100%) as a colorless oil. 1H NMR (CDCl3) δ 0.89–0.93 (t, J=7 Hz,
3H, CH3), 1.33–1.43 (m, 4H, CH2), 1.56 (brs, 1H, OH), 1.70–1.76 (m, 2H, CH2), 3.86–3.90
(t, J=7 Hz, 2H, CH2-O), 4.04 (s, 2H, Ar-CH2-Ar), 4.64 (s, 2H, CH2-OH), 6.68–6.71 (m, 2H,
Ar-H), 6.74 (s, 1H, Ar-H), 7.14–7.28 (brm, 4H, Ar-H), 7.39–7.40 (m, 1H, Ar-H). 13C NMR
(CDCl3) δ 14.59, 23.05, 28.77, 29.55, 39.11, 63.81, 68.42, 112.46, 115.76, 121.43, 127.41,
128.55, 128.95, 130.02, 131.17, 139.14, 139.24, 142.68, 159.51.
4-n-Hexyl-2-(3-methoxybenzyl)benzyl alcohol (25)
Compound 25 was prepared from 18h in a manner analogous to that of 22. The resulting oil
was purified using medium pressure column chromatography (petroleum ether/acetone, 8:2)
to provide 25 (2.21 g, 92%) as a colorless oil. 1H NMR (CDCl3) δ 0.85–0.89 (t, J=6 Hz, 3H,
CH3), 1.26–1.29 (m, 6H, CH2), 1.53–1.60 (m, 2H, CH2), 2.54–2.59 (t, J=8 Hz, 2H, CH2-
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Ar), 3.76 (s, 3H, OCH3), 4.03 (s, 2H, Ar-CH2-Ar), 4.52 (s, 2H, CH2-OH), 6.68–6.74 (m, 3H,
Ar-H), 7.00–7.30 (brm, 4H, Ar-H). 13C NMR (CDCl3) δ 14.62, 23.18, 29.54, 32.01, 32.28,
36.17, 39.16, 55.66, 63.75, 111.82, 115.10, 121.10, 127.41, 129.30, 130.02, 131.47, 136.70,
138.79, 143.03, 143.44. IR (Film) 3365 cm−1.
4-n-Hexyl-benzoylcyanide (26)
Trimethysilyl cyanide (0.62 mL, 4.67 mmol) was slowly added under N2 to a well stirred
solution of 4-n-hexylbenzoyl chloride (1.0 g, 4.45 mmol) in anhydrous CH2Cl2 (10 mL).
Tin(IV) chloride (0.10 mL, 0.850 mmol) was added over 30 min to the solution at room
temperature and the mixture was allowed to stir for 2.5 h during which time the solution
gradually turned from yellow to a dark brown. Ice cold water (30 mL) was added and the
mixture was extracted with CH2Cl2 (3 × 30 mL). The organic extracts were combined, dried
(MgSO4) and concentrated under reduced pressure to provide a brown oil. The oil was
purified using medium pressure column chromatography (petroleum ether/acetone, 9.5:0.5)
to provide 26 (0.820 g, 85%) as a pale yellow oil. 1H NMR (CDCl3) δ 0.86–0.88 (t, J= 8 Hz,
3H, CH3), 1.13 (s, 6H, CH2), 1.60–1.65 (m, 2H, CH2), 2.7–2.75 (t, J=7.8 Hz, 2H, Ar-CH2),
7.38–7.41 (d, J=8 Hz, 2H, Ar-H), 8.04–8.07 (d, J=8 Hz, 2H, Ar-H). 13C NMR (CDCl3) δ
14.59, 23.08, 29.43, 31.37, 32.14, 36.92, 130.17, 131.25, 154.24. IR (Film) 2221, 1687
cm−1.
2-(4-Bromophenyl)-2-phenylacetonitrile (27)
Bromine (0.82 g, 5.1 mmol) was slowly added over 1 h to 4-bromophenylacetonitrile (1.00
g, 5.10 mmol) at 110 °C (oil bath). The temperature was maintained between 105 °C and
110 °C for 30 min until the evolution of HBr had ceased. The solution was allowed to cool
to room temperature and a steady stream of nitrogen was passed over the solution (30 min).
The resulting yellow oil was dissolved in anhydrous benzene (1.20 g, 15.0 mmol) and AlCl3
(0.680 g, 5.10 mmol) was added. The solution was heated at reflux (3 h), cooled to room
temperature and poured onto ice (25 g). The solution was made acidic to pH 2 with 5% HCl
and extracted with Et2O (3 × 35 mL). The organic extracts were combined, washed with
water (50 mL), sat. NaHCO3 (50 mL), brine (50 mL), dried (MgSO4) and concentrated
under reduced pressure to provide a pale yellow semisolid. The semisolid was recrystallized
from absolute EtOH to provide 27 (0.650 g, 46%) as pale yellow crystals; mp 80–82 °C.
(Lit48 mp 79–81 °C). 1H NMR (CDCl3) δ 5.10 (s, 1H, CH), 7.21–7.53 (brm, 9H, Ar-H). IR
(KBr) 2246 cm−1.
(4-n-Hexylphenyl)(phenyl)methanone (28)
AlCl3 (2.36 g, 17.8 mmol) was added slowly at 0 °C to 4-n-hexylbenzoyl chloride (2.00 g,
8.90 mmol) in anhydrous benzene (50 mL). The suspension was warmed to room
temperature and heated at reflux (2 h). The solution was then cooled to room temperature
and poured onto ice (30.0 g). The suspension was made acidic with 5% HCl (≈ 50 mL) and
extracted with EtOAc (3 × 45 mL). The organic extracts were combined, washed with sat.
NaHCO3 (50 mL), water (50 mL), brine (50 mL), dried (MgSO4) and concentrated under
reduced pressure to provide 28 (2.00 g, 87%) as a pale yellow oil. The product was of
sufficient purity to use in the next step. 1H NMR (CDCl3) δ 0.86–0.91 (t, J=7 Hz, 2H, CH3),
1.25 (s, 6H, CH2), 1.62–1.67 (m, 2H, CH2), 2.65–2.71 (t, J=8 Hz, 2H, CH2), 7.25–7.80
(brm, 9H, Ar-H). IR (Film) 1662 cm−1.
2-(4-n-Hexylphenyl)-2-hydroxy-2-phenylacetonitrile (29)
Trimethylsilyl cyanide (0.440 g, 4.51 mmol) was added to 28 (4-n-hexylphenyl)
(phenyl)methanone (1.00 g, 3.76 mmol) and zinc iodide (cat. amount) in CH2Cl2 (5 mL).
The suspension was heated at reflux (2 h), cooled to room temperature, and concentrated
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under reduced pressure to provide a pale yellow oil. The oil was dissolved in THF (5 mL)
and 3 M HCl (3 mL) was added. The suspension was heated at reflux (1 h), cooled and
water (100 mL) was added. The mixture was extracted with EtOAc (3 × 20 mL) and the
organic extracts were combined, dried (MgSO4) and concentrated under reduced pressure to
provide a pale yellow oil that was purified using medium pressure column chromatography
(petroleum ether/acetone, 8:2) to provide 29 (0.680 g, 62%) as a colorless oil. 1H NMR
(CDCl3) δ 0.83–0.87 (t, J=8 Hz, 2H, CH3), 1.28 (s, 6H, CH2), 1.53–1.58 (m, 2H, CH2),
2.57–2.62 (t, J=8 Hz, 2H, CH2), 3.27 (brs, 1H, OH), 7.18–7.56 (brm, 9H, Ar-H). IR (Film)
3403 cm−1.
2-(4-n-Hexylphenyl)-2-phenylacetonitrile (30)
A NaBH4 pellet (1.00 g, 26.4 mmol) was added to a well stirred solution of 29 2-(4-n-
hexylphenyl)-2-hydroxy-2-phenylacetonitrile (0.550 g, 1.88 mmol) in trifluoroacetic acid
(15 mL). The viscous purple mixture was stirred at room temperature for 2 h and
concentrated under reduced pressure. Water (40 mL) was added and the suspension was
extracted with EtOAc (3 × 20 mL). The organic extracts were combined, dried (MgSO4) and
concentrated under reduced pressure to provide a pale purple oil that was purified using
medium pressure column chromatography (petroleum ether/acetone, 8:2) to provide 30
(0.350 g, 67%) as a colorless oil. 1H NMR (CDCl3) δ 0.85–0.89 (t, J=8 Hz, 2H, CH3), 1.28
(s, 6H, CH2), 1.52–1.59 (m, 2H, CH2), 2.55–2.60 (t, J=7.8 Hz, 2H, CH2), 5.20 (s, 1H, CH),
7.15–7.36 (brm, 9H, Ar-H). 13C NMR (CDCl3) δ 14.64, 23.14, 29.51, 31.86, 32.24, 36.10,
42.85, 128.15, 128.28, 128.70, 129.74, 129.75. IR (Film): 2246 cm−1.
Molecular Modeling—Molecular modeling investigations were conducted using the
SYBYL molecular modeling package (version 7.1, 2005, Tripos Associates, St. Louis, MO)
on MIPS R14K- and R16K-based IRIX 6.5 Silicon Graphics Fuel and Tezro workstations.
Molecular mechanics-based energy minimizations were performed using the Tripos Force
Field with Gasteiger-Hückel charges, a distance-dependent dielectric constant ε = 4 and a
non-bonded interaction cutoff = 8 Å and were terminated at an energy gradient of 0.05 kcal/
(mol·Å).
The primary sequences of the human dopamine D3 (P35462), human muscarinic cholinergic
M1 (P11229), human vasopressin V1a (P37288), human adrenergic β2 (P07550), human δ-
opioid (P41143), human 5-HT2A (P28223), human dopamine D2 (P14416) and bovine
rhodopsin (P02699) receptors were retrieved from the ExPASy Proteomics Server
(http://www.expasy.org/) at the Swiss Institute of Bioinformatics. An alignment profile
consisting of the D3, M1, V1a, β2, δ-opioid and bovine rhodopsin receptors was created that
reproduced the alignment of Bissantz, et al.79 An unambiguous (i.e. highly conserved
residues previously identified80, 81 are aligned and no insertions or deletions in the helical
regions) alignment of the 5-HT2A sequence with the aforementioned profile was performed
using the ClustalX82 program. Within ClustalX, the slow-accurate alignment algorithm was
used, the BLOSUM matrix series83 was employed and the gap opening penalty was
increased from 10.0 to 15.0 to help maintain the continuity of the transmembrane helical
segments. As in Bissantz, et al.,79 the alignment was carried out in two separate steps: the
first alignment included all residues from the N-terminus to the i3 loop and the second
alignment included all residues from the i3 loop to the C-terminus. Manual adjustment of the
ClustalX alignment was also required to properly align the disulfide-forming cysteine
residues in the e2 loop. The D2 sequence was subsequently aligned with that of 5-HT2A to
identify loci within the binding sites of the two receptors where cognate amino acids differ
and to identify those that may be responsible for 5-HT2A/D2 selectivity. The resulting
alignment is presented in Figure 3.
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The alignment described above was used as the basis for subsequent homology modeling of
the 5-HT2A receptor. In light of the growing evidence35, 79, 84–91 that the binding of agonists
versus antagonists may be more effectively modeled using at least two distinct static
receptor models rather than a single static model, and our own observation that the agonist/
antagonist properties of the 1-(2,5-dimethoxyphenyl)-2-aminopropane derivatives may be
modulated by the nature of the substituent at the 4-position of the phenyl ring,15 separate
agonist and antagonist 5-HT2A models were generated. The automodel routine in the
MODELLER 8v1 software package92, 93 was thus used to generate an initial population of
100 5-HT2A receptor models. These models were constructed based on homology to bovine
rhodopsin (chain A of PDB entry = 1U19), whose coordinates were downloaded from the
RCSB Protein Data Bank (http://www.rcsb.org).
To maximize the variation in the sidechain conformations of the MODELLER-generated
receptors, the residues falling within 12.0 Å of the retinal ligand in 1U19 were mutated to
alanine. These residues are highlighted with a green background in Figure 3. This approach,
which has been used to successfully model α2-adrenergic receptors,94 allows MODELLER
to more fully explore sidechain conformational space, since the sidechains may then be
placed onto the backbone without the added constraints imposed by the existing rhodopsin
sidechains. This also ameliorates the problem of retinal leaving behind a “ghost site” in the
newly-created 5-HT2A receptors.95
In addition to mutating the residues lining the 1U19 binding cavity to alanine, two other
important aspects relating to the transfer of 3-D information from the 1U19 template to the
5-HT2A models (particularly in the less well-conserved regions) were specifically addressed.
First, instead of attempting to accurately model the i3 loop of 5-HT2A (which is 40 residues
longer than rhodopsin’s), the backbone of the i3 loop of rhodopsin was transferred to the 5-
HT2A models and the residues therein mutated to glycine. These residues are highlighted
with a purple background in Figure 3. This effectively created a tether that would keep the
helices in place while having a minimal impact on the remaining portion of the receptor
during minimizations and/or dynamics simulations. Pogozheva, Lomize and Mosberg96
have used a similar technique to build opioid receptors in which a contiguous primary amino
acid sequence for the receptor was necessary. Second, since the N- and C-terminal domains
of bovine rhodopsin and 5-HT2A are very dissimilar in terms of both sequence homology
and length, and since these domains are not believed to be important for the binding of small
molecules97, 98, these features were not included in the 5-HT2A models.
Each of the initial 100 5-HT2A models thus generated was energy-minimized as described
above with a maximum of 100,000 iterations and with no constraints. The process of then
selecting an agonist and an antagonist model from the receptor population was facilitated by
the use of the automated docking program GOLD (version 3.0.1).99, 100 A high-potency
agonist (DOB, 2b, Ki = 41 nM) and an antagonist (ketanserin, Ki = 0.4 nM) were selected as
reference ligands and each was docked into all 100 receptors using the GOLD program. For
DOB, separate docking runs were performed for each explicitly represented stereoisomer
((R)- and (S)- forms of 2b = 2 isomers) since each isomer shows low nanomolar binding
affinity at the 5-HT2A receptor. Standard default settings were used (no speed-up), early
termination was disabled, and 10 genetic algorithm (GA) runs were performed for each
ligand. The ChemScore101 fitness function was used, and the binding site was defined to
include all residues within a 15.0-Å radius of the D1553.32 Cγ carbon atom. A docking
constraint was also enforced that biased the docking results toward solutions in which the
ligand was hydrogen bonded to the conserved D1553.32 sidechain. When these initial
docking runs were complete, the lists of ChemScores for each isomer were tabulated (each
reference ligand isomer was docked into each of the 100 MODELLER-generated receptors)
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and sorted best to worst (highest to lowest for ChemScore in GOLD). The top-scoring
complexes for each reference ligand are summarized in Supplemental Table 4.
The top-scoring receptor-ligand complexes for each of the reference compounds were then
inspected visually to ensure that the receptor formed a chemically intuitive complex with the
ligand and that the receptor-ligand complex could account for the observed point mutation
data. High-scoring complexes that did not meet this requirement were discarded. Ligand-
receptor complexes were discarded for a variety of reasons, including 1) the docked solution
for DOB did not accept a hydrogen bond from the receptor at either the 2- or 5-position
(rationale: methoxy groups are necessary for high affinity of the smaller 4-substituted
phenylethylamines [Ki = 1770 nM, 3b; Ki = 41 nM, 2b]), 2) the docked solution for DOB
did not interact with F340 (rationale: DOB most likely binds in the receptor site in the same
manner as does DOI (Supplemental Figure 2), which loses all affinity for the F340A mutant
(Table 2)), 3) the docked solution for ketanserin could not explain the effects of mutagenesis
at F340, Y370 and/or W76 (Table 3), and 4) the e2 loop of the receptor was incorrectly
modeled (rationale: MODELLER occasionally placed the e2 loop segment that joins the top
of TM4 to the disulfide bond farther down in the receptor site than the segment joining the
disulfide bond to the top of TM5 — the reverse of what is seen in the bovine rhodopsin
crystal structure). A complete listing of the twelve top-scoring receptor-reference ligand
complexes and comments on their binding modes is presented in Supplemental Table 4.
The ChemScores for the 100 top complexes covered a wide range (R(−)-DOB, 1.41 to
33.52; S(+)-DOB, 3.06 to 30.71; ketanserin, −31.84 to 35.21), a result of the receptor
population containing members that exhibited both very high and very low degrees of
complementarity to the docked ligands. The top-scoring receptors for a given ligand tended
to have similar high scores (Supplemental Table 4), but the corresponding binding modes of
the docked ligands were very different. It was thus necessary to use additional information
from receptor mutagenesis and ligand SAR to eliminate from consideration those that were
not consistent with this data and to select the most appropriate receptor models (vide supra).
Of course, reconciliation of relevant experimentally-derived data with molecular models is a
necessary part of any modeling study. Seven of the top twelve receptor models are common
to both R(−)-DOB and S(+)-DOB. Interestingly, five of the top twelve receptor models for
ketanserin are also found in the top receptor lists of either R(−)-DOB or S(+)-DOB. It
should also be noted that for a given receptor-ligand model, the set of docked solutions from
the ten GA runs tended to be qualitatively similar, differing only slightly in the ligands’
relative position and orientation within the binding site. For each of the reference ligands,
then, the final receptor model chosen was the highest scoring chemically intuitive complex.
For DOB, the same receptor model was coincidentally chosen for each of the two
stereoisomers. In this selected agonist model, the DOB isomers docked in a similar fashion
(Supplemental Figure 2).
The agonist and antagonist 5-HT2A models were subsequently analyzed using
PROCHECK102 and the ProTable facility with in SYBYL to assess the geometric integrity
of various structural elements (bond lengths, torsion angles, etc.) within each receptor.
Unusual and unfavorable geometries were interactively corrected as necessary. There were
two such regions in both the agonist and antagonist receptors. The first involved the region
of TM7 proximal to position 7.43 where the retinal chromophore is covalently bound in
rhodopsin. Backbone geometries in this region were visibly non-optimal (kinked), so the
residues in the region V3647.37 to A3747.47 were assigned ideal alpha helix coordinates
using SYBYL 7.1. A second visibly distorted region at location L2365.40 to V2415.45 was
refined in a similar way. The modified receptors were then energy-minimized as described
for the initial 5-HT2A receptors prior to docking. The final models are depicted together with
the A chain of rhodopsin (1U19) in Supplemental Figure 1.
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Ligand molecules were sketched manually using SYBYL 7.1 (Tripos, Inc., St. Louis, MO)
and assigned three-dimensional coordinates using the CONCORD (v.6.1.0) facility within
SYBYL. Since the synthesized and tested compounds are racemic mixtures in most if not all
cases, R/S isomers were explicitly represented for each ligand where necessary. GOLD was
used to dock the ligands into the agonist and antagonist 5-HT2A models in an automated
fashion under the same conditions as described above for the receptor selection phase.
Ligand preference for a particular receptor was determined by the difference in the
ChemScore fitness function values for the agonist and antagonist receptor solutions
(Supplemental Table 2). However, there was one exception: AMDA (1a), which was
predicted to have a slight preference for the agonist receptor, was associated with the
antagonist model on the strength of the F3406.52L mutation data, as described earlier. Final
docked ligand-receptor complexes were energy-minimized as described above for the initial
5-HT2A models. The minimized complexes were further subjected to a short molecular
dynamics simulation (Tripos Force Field, Gasteiger-Hückel charges, distance-dependent
dielectric = 4.0, fixed aggregate = all residues > 8.0 Å from the GOLD-docked solution, 100
ps simulation time, 300K) to provide further evidence of the veracity of the docked
solutions.
Affinity Determinations—Binding assays and data analysis were performed as
previously described using [3H]ketanserin as the radioligand and stably transfected NIH3T3
cells expressing the 5-HT2A receptor (GF-62 cells).103 The F339L and F340L mutants were
prepared and assayed as previously described.104
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1a. Schematic representation of sterically accessible binding sites within the 5-HT2A
receptor provisionally considered to be the agonist site (Site 1) and the antagonist site (Site
2).28, 29 1b. Connolly channel depicting Site 1 and Site 2 within the 5-HT2A receptor model.
The GOLD-generated docking mode for AMDA is also shown (CPK space-filling model) to
highlight the complementarity between the shape of Site 2 and the fold angle of the AMDA
ring system. D1553.32 is shown for reference (ball-and-stick model).
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The proposed binding mode of selected compounds docked and energy-minimized in the 5-
HT2A receptor models. Carbon atoms of the ligand are colored green. Residues whose heavy
atoms fall within 4 Å of the bound ligand heavy atoms are displayed. A light blue
transparent trace indicates the position of the receptor backbone. Hydrogen bonding
interactions are indicated with a thin black line and H-bond donor-acceptor distances (in Å)
are indicated in blue. The antagonist models are displayed from a common point of view in
which TMs 6, 7 and 1 are closest to the viewer. A. R(−)-DOB (R(−)-2b); agonist model. B.
ketanserin; antagonist model. C. AMDA (1a); antagonist model. D. (S)-3-hydroxy-AMDA
(1g); antagonist model. E. (S)-3-phenylpropylAMDA (1c); antagonist model. F. (R)-2c;
antagonist model.
Runyon et al. Page 37














Alignment of the bovine rhodopsin, 5-HT2A and D2 receptor sequences. Sequence positions
highlighted in red indicate highly conserved amino acids among the Class A GPCR family
that serve as reference positions in the general Ballesteros-Weinstein110 numbering system.
The traditional numbering is also given for the 5-HT2A (top) and D2 (bottom) sequences.
Bovine rhodopsin residues highlighted in green indicate positions that are within 12.0 Å of
bound retinal; these were mutated to alanine prior to the 3-D model building phase. Bovine
rhodopsin residues highlighted in purple indicate positions in the third intracellular loop that
were mutated to glycine in the 5-HT2A sequence and in subsequent 5-HT2A models.
Residues highlighted in yellow boxes in the 5-HT2A sequence represent those that are
closest to AMDA (within 4.5 Å heavy atom to heavy atom) in the antagonist model. Note:
The D3, M1, V1a, β2 and δ-opioid GPCR sequences have been omitted for brevity and clarity
(see text for details). The figure was created using ALSCRIPT.111
Runyon et al. Page 38














Reagents and Conditions: (a) 1; 2-amino-2-methyl-1-propanol, CH2Cl2. 2; SOCl2, Toluene;
(b) sec-butyllithium, THF −78 °C; (c) 5% HCl 10 h; (d) 10% Pd/Charcoal, HClO4 (cat), 2-
PrOH; (e) BH3-THF; (f) PCC, CH2Cl2; (g) Trimethylsilyl cyanide, CH2Cl2; (h) LiAlH4,
THF; (i) Eaton’s Reagent, PPA or Methane sulfonic acid; (j) BBr3, CH2Cl2.
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Reagents and Conditions: (a) THF, 10 °C; (b) Conc. HCl, MeOH; (c) PPA, room temp; (d)
SnCl2, EtOH.
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Reagents and Conditions: (a) NBS, CCl4; (b) AlCl3, Benzene; (c) KOH, Ethylene glycol; (d)
BH3-THF; (e) PCC, CH2Cl2; (f) 1; Allylbenzene, 9-BBN 2; PdCl2(dppf), NaOH, THF.
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Structures of AMDA (1a), DOB (2b) and ketanserin.
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Table 2











[3H]Ketanserin labeled cloned 5-HT2A sites.
Ki values at the wild type receptors are from Table 1.
Standard errors typically range between 15–25% of the Ki value.
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Table 3
The effect of various mutations on the binding affinity of ketanserin for 5-HT2A mutants.
Mutation Effect Ref. Commentsa
W761.34A 10-fold ↓ in affinity 44 Interacts with W3677.40.
D1202.50N 10-fold ↓ in affinity 105 Widely conserved across GPCRs.
F1252.55L no effect 104 Not in binding pocket.
F1252.55L no effect 44 “
F1252.55L no effect 106 “
F1252.55S 2-fold ↓ in affinity 104 “
F1252.55S no effect 107 “
M1322.62L no effect 107 Not in binding pocket.
T1342.64A no effect 107 Inaccessible when e2 loop is in cavity.
D1553.32A no detectable binding 108 Ammonium binding site.
D1553.32E no detectable binding 108 “
D1553.32N 75-fold ↓ in affinity 105 “
D1553.32N no detectable binding 108 “
D1553.32Q no detectable binding 108 “
S1593.36A no effect 45 One turn below D1553.32.
S1593.36C no effect 45 “
D1723.49N no effect 105 Conserved D/ERY motif.
W2004.50A no effect 44 Widely conserved; not in binding site.
S2395.43A < 2-fold ↑ in affinity 47 In Site 1.
F2405.44A 2-fold ↑ in affinity 47 Not in binding pocket.
S2425.46A ~2-fold ↑ in affinity 109 In Site 1.
F2435.47A 4.5-fold ↓ in affinity 47 Interacts with F3406.52.
F2445.48A 2-fold ↓ in affinity 47 Not in binding pocket.
W3366.48A 900-fold ↓ in affinity 44 “Toggle switch”; Site 1/Site 2.
F3396.51A 10-fold ↓ in affinity 104 One turn above W3366.48.
F3396.51L 25-fold ↓ in affinity 104 “
F3396.51L 8-fold ↓ in affinity 44 “
F3396.51L 25-fold ↓ in affinity 106 “
F3396.51L 20-fold ↓ in affinity 107 “
F3396.51Y 7-fold ↓ in affinity 104 “
F3406.52A 2-fold ↓ in affinity 104 Interacts with F2435.47.
F3406.52L no effect 104 “
F3406.52L 2-fold ↓ in affinity 44 “
F3406.52L no effect 107 “
F3406.52L 2-fold ↑ in affinity 106 “
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Mutation Effect Ref. Commentsa
F3406.52Y 70-fold ↓ in affinity 104 “
F3657.38L 4-fold ↓ in affinity 44 Not in binding site.
W3677.40L no detectable binding 44 Interacts with W761.34.
Y3707.43A 18-fold ↓ in affinity 44 In Site 2.
F383A 3.5-fold ↓ in affinity 44 In the turn between TM7 and Helix 8.
a
Comments refer to the antagonist model described here.
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